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“Much has happened during the last eight or nine years. Some changes 
came promptly, like in her skin and hair, and eye contact when 
brushing her teeth. But we waited long before noticing any reactions 
when we talked to her. But lately she has been escalating, repeating 
words and asking for things. Before the diet everything about her was 
negative, now she smiles and appreciates company. We can take her 
along on trips and to concerts.” (Caregiver)  
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Summary 
Phenylketonuria (PKU) is an inborn error of metabolism, due to a defective liver 
enzyme the conversion of the amino acid phenylalanine (phe) to tyrosine is not 
functioning. PKU was first described in 1934 by the Norwegian doctor and scientist 
Asbjørn Følling. Without treatment persons with PKU suffer permanent neurological 
damage and mental retardation. Today newborn screening programmes result in early 
diagnosis. Dietary treatment is started shortly after birth to prevent brain damage. The 
intake of phe is restricted by allowing only small amounts of protein in the diet. 
Requirements are met by taking a protein substitute containing amino acids, vitamins 
and minerals. Special low protein food secure energy requirement. For a person with 
brain damage due to late diagnosed PKU, dietary treatment may ease neurological 
and behavioural signs. Positive effects are reported for a majority of late diagnosed 
patients after treatment start. Literature on how these persons and their caregivers 
translate the advice and prescriptions from doctors and dietitians into an everyday 
diet is lacking. 
The objective of the present study was to analyse the composition of dietary intake 
and describe how adults with PKU and brain damage manage the diet.  
Methods: 
An observational cross-sectional study was performed on 21 subjects with brain 
damage and adhering to a PKU diet: 8 men, 13 women; 26 – 66 years of age. Seven 
mildly retarded subjects living independently constituted group A. Group B consisted 
of fourteen severely retarded subjects needing continuous support and living in group 
homes. Data were collected by a four-day weighed food registration, a semistructured 
interview, blood samples and hospital charts. Descriptive statistics were used in 
analysing. 
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Results: 
Serum phe was lowered by the diet to a median 472µmol/L. Median intake of 
selected nutrient: 1.02 g/kg protein (substitute and natural protein), 26 E% from fat, 
15 E% from added sugar and 1.7 g/MJ of dietary fibre. The median intake of fruit and 
vegetables was 370g/d, comparable to the Norwegian mean intake. Fortification 
resulted in excessive intakes of micronutrients and high blood concentrations of 
folate and vitamin B12. Other blood parameters as iron, zinc or magnesium, did not 
show the same effect despite high intakes. The intake was above estimated upper 
limit for a few nutrients, as iron.  
Discussion and conclusion: 
The study showed that adults with PKU and brain damage could manage a diet 
according to nutritional recommendations. However, this required great efforts and 
special considerations regarding food choice. The fortification of micronutrients is 
excessive and the doses and compounds used need evaluation in order to compose an 
optimal diet. The subjects in group A faced great challenges in adhering to the diet. 
Practical support was needed to maintain low serum phe levels and compose a varied 
diet. Managing the diet in group B depended on mutual agreement and a basic 
knowledge of PKU among the group home staff, this improved cooperation and 
supported the responsible caregivers. Caregivers in group B requested information 
and knowledge, whereas the psychological and emotional aspects of adhering were 
more important for subjects in group A. 
This study has provided new knowledge that can prove important in regard to giving 
dietary advice and in organising follow-up of persons with PKU and brain damage. It 
may also stimulate an improved cooperation between local and central systems for 
treatment and support. The results of the present study also show that further 
investigation into the nutritional impact of a semi-synthetic diet is required. 
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Sammendrag på norsk 
Fenylketonuri (PKU) er en medfødt stoffskiftesykdom. Årsaken er et ødelagt 
leverenzym omdannes ikke aminosyren fenylalanin (phe) til tyrosin som vanlig. PKU 
ble først beskrevet I 1934 av den norske legen og vitenskapsmannen Asbjørn Følling. 
Uten behandling vil personer med PKU utvikle varig nevrologisk skade og 
utviklingshemning. I dag fører screening program for nyfødte til tidlig diagnose. 
Diettbehandlingen starter kort tid etter fødselen for å forhindre hjerneskade. Inntaket 
av phe begrenses ved å tillate svært lite naturlig protein i dietten. Proteinbehovet blir 
dekket gjennom en proteinerstatning med aminosyrer, vitaminer og mineraler. 
Spesialprodusert lavproteinmat brukes for å sikre energibehovet. For personer med 
utviklingshemning på grunn av sen PKU-diagnose kan behandlingen lette 
nevrologiske og adferdsmessige tegn. Dietten kan ikke endre hjerneskader som alt er 
oppstått, men positiv effekt er rapportert for de flest personer som starter behandling 
sent. Det er mangel på litteratur om hvordan disse menneskene og deres hjelpere 
oversetter råd fra leger og kliniske ernæringsfysiologer til et daglig kosthold. 
Formålet med studien var å analysere sammensetningen av kostholdet og beskrive 
hvordan voksne med PKU og hjerneskade mestret dietten. 
Metoder: 
En observasjonsstudie ble foretatt på 21 deltakere med utviklingshemning og PKU-
diett: 8 menn og 13 kvinner, alder 26 – 66 år. Sju personer, med mild 
utviklingshemning, utgjorde gruppe A. Gruppe B besto av fjorten alvorlig 
utviklingshemmede personer med heldøgns hjelp i omsorgsboliger. Data ble samlet 
gjennom en firedagers veid kostregistrering, semistrukturert intevju, blodprøver og 
journaler. Deskriptive statistiske metoder ble brukt i analyse av data. 
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Resultater: 
Medianen for serum-phe nivået var 472 µmol/L. Inntak av visse næringsstoffer viste 
en median på: 1,02 g/kg fra protein (erstatning og naturlig protein), 26 E% fra fett, 15 
E% fra tilsatt sukker og 1,7 g/MJ kostfiber. Medianinntak av frukt og grønnsaker var 
370 g/d, omtrent som norsk gjennomsnittsinntak. Forsterkninger ga svært høyt inntak 
av mikronæringsstoffer og høye konsentrasjoner i blod for folat og vitamin B12. 
Denne effekten var ikke tilstede i blodprøvesvar for jern, sink eller magnesium, på 
tross av høye inntak. Inntaket av visse næringsstoffer, som jern, var over anbefalt 
øvre grense. 
Diskusjon og konklusjon: 
Studien viste at voksne med hjeneskade og PKU klarte å holde en diett som tilsvarte 
ernæringsmessige anbefalinger. Men dette var krevende og trengte spesiell omtanke i 
matvarevalg. Forsterkningen med mikronæringstoffer ga overdrevent høye doser, 
mengde og typer må vurderes videre for at dietten skal bli mer optimal. Deltakerne i 
gruppe A opplevde store utfordringer i å holde dietten. De hadde behov for praktisk 
hjelp for å holde serum-phe lavt og for å sette sammen et variert kosthold. For å holde 
dietten i gruppe B krevdes samforståelse og basiskunnskap om PKU blant ansatte i 
boligen, dette bedret samarbeidet og ga støtte til ansatte med hovedansvar. 
Omsorgsarbeidere i gruppe B ønsket informasjon og kunnskap, mens de 
psykologiske og følelsesmessige aspektene ved å følge dietten var viktigst i gruppe 
A. 
Studien har bidratt med ny kunnskap som kan være viktig i diettrådgivning og i 
organisering av oppfølgingen av personer med PKU og hjerneskade. Den kan også 
stimulere samarbeidet mellom lokale og sentrale systemer for behandling og 
støttetiltak. 
Resultatene viser også behov for videre forskning på ernæringsmessige følger av å 
leve på en slik delvis kunstig sammensatt diett. 
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Abbreviations and terminology 
AA  Arachidonic acid, essential long chain polyunsaturated fatty acid, 
synthesised by elongation of linoleic acid. 
Adherence  The extent to which a person’s behaviour corresponds with agreed 
recommendations from a health care provider. 
Alertness  Emotional state of attention and responsiveness, being aware of and 
interested in the surroundings. 
BH4 Tetrahydrobiopterine, coenzyme for PAH. 
BMI Body mass index, kg/m2. 
BMR Basal metabolic rate. 
DHA Docosahexaenoic acid, essential long chain polyunsaturated fatty 
acid, synthesised by elongation of α-linolenic acid. 
Group home Community based residence for disabled persons needing support. 
Group homes for mentally retarded persons with different diagnoses 
have replaced larger institutions. Staff members on duty have 
responsibility for one or more residents at the time. Four to six 
residents live in separate apartments constituting one group home. 
ICD 10 International statistical classification of diseases administered and 
updated by the World Health Organisation (WHO). 
Inborn error of 
metabolism  
A genetic failure in cellular metabolism, often due to malfunction of 
specific enzymes. PKU is an inborn error of protein (amino acid) 
metabolism  
LCPUFA Long chain polyunsaturated fatty acids, from food or synthesised in 
the body by elongation of linoleic acid and α-linolenic acid.  
LNAA Long neutral amino acids, essential amino acids. 
Mental retardation Limitations or halt in childhood development resulting in general 
learning disabilities and intelligence quotients (IQ) below 70 (coded 
as F70-F79 in ICD10). 
MUFA Monounsaturated fatty acids. 
Natural foods Food and food products for general consumption, not specially 
produced or intended for protein reduced diets, containing normal 
amounts of protein. 
Neurotransmitter Chemical compounds transmitting signals between neurons. 
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Newborn screening Pre-symptomatic blood test taken one of the first days of life, in order 
to detect and treat rare disorders like PKU. 
PAH Phenylalanine hydroxylase. 
PAL Physical activity level. The ratio of total energy expenditure divided 
by BMR, used for quantifying and comparing energy expenditure. 
Phe Phenylalanine. 
Phenylalanine 
hydroxylase 
Enzyme converting phenylalanine to tyrosine (genetically defined in 
the database Online Mendelian Inheritance in Man OMIM 261600). 
Phenylalanine
  
Essential amino acid, not normally metabolized in PKU. 
Phenylketonuria An inborn error of metabolism caused by a deficiency of human 
phenylalanine hydroxylase. (coded as E70.0 in ICD 10). 
PKU   Phenylketonuria 
Protein reduced 
food  
Special food products produced with little or no protein,intended as 
substitute for natural foods with higher protein content in protein 
reduced diets. Also called low protein food. 
Protein substitute Mixture of amino acids used in treatment of inborn errors of protein 
metabolism. For treatment of PKU, the protein substitutes are devoid 
of phe and often supplemented with minerals and vitamins. 
PUFA Polyunsaturated fatty acids, essential fatty acids. 
Self-mutilation Inflicting harm or injury on oneself, can be a symptom of mental or 
emotional disturbances. Often seen in untreated PKU. 
Serum phe Serum phenylalanine concentration, unit of measurement is µmol/L. 
SFA Saturated fatty acids. 
Tyrosine Amino acid. Tyrosine becomes an essential amino acid in PKU 
because the conversion of phenyalanine to tyrosine by PAH is 
impaired. 
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“Being on diet is like becoming a new person. You are happier, more 
energetic, more awake, - but you sleep better at night.” (Subject) 
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1. Introduction 
Phenylketonuria (PKU) is an inborn error of protein metabolism. The disorder is due 
to a defect in phenylalanine hydroxylase (PAH); a liver enzyme catalysing the 
conversion of the amino acid phenylalanine (phe)  to tyrosine (1-4). High levels of 
serum phenylalanine and low serum levels of tyrosine are diagnostic hallmarks for 
this inborn error. These findings are associated with permanent damage to the central 
nervous system. A diet, containing only small amounts of natural protein restricts the 
intake of phenylalanine and can prevent mental retardation and physical damage from 
PKU. Presymptomatic diagnosis is verified in the national newborn screening 
programme allowing dietary treatment to be started within days or a few weeks after 
a child with PKU is born. This is preventing brain damage in persons with PKU (1-
4).  
1.1 Phenylketonuria, symptoms and development 
PKU is an autosomal recessive disorder. Children, homozygotic, or compound 
heterozygotic, for a mutant PAH-gene are born symptom free, but develop symptoms 
if intake of dietary phenylalanine (phe) is over their individual tolerance. On a normal 
diet serum phenylalanine becomes elevated to toxic levels within a few days after 
birth (1). When the level of phenylalanine in serum is persistently over 400 µmol/L, 
treatment is started. Normal levels are below 100 µmol/L. If left untreated, the high 
phe levels are associated with permanent brain damage and neuropsychological 
problems (1). 
The brain damage develops progressively if blood phenylalanine is high over time, 
and treatment should be started within the first two to four weeks of life to avoid 
permanent damage (1;3;5). The mechanisms of damage and at what concentration 
levels phenylalanine starts to be neurotoxic, are not fully understood. Phenylalanine 
competes with other large neutral amino acids (LNAA’s) for the same carrier to pass 
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the blood-brain barrier. When PKU is untreated, there will be an imbalance of brain 
amino acids due to the high concentration of phenylalanine in serum (6;7). The 
resulting high concentration of phenylalanine in the brain is neurotoxic, leading to 
defects in neuronal growth and myelination. There will be a relative deficiency of 
tyrosine and tryptophane, leading to deficient production of the neurotransmitters 
dopamine, noradrenaline and serotonine (6-8).  
Parents of untreated or late treated patients report that developmental deficiencies 
started to be obvious after a few months of life (personal communications from 
mothers to older patients with late treatment start). High blood concentrations of 
phenylalanine lead to formation of phenylketones, giving urine and sweat an 
unpleasant, musty odour. The tyrosine deficiency results in light pigmentation of the 
skin and hair, and eczema like skin lesions, due to lack of melanine production (1-4). 
Treatment will result in normalisation of body odour and pigmentation. If diet is 
started in infancy or early childhood, before the brain damage is fully developed, 
further aggravation may be halted. Even if treatment is started late in childhood or in 
the adult years neurological and behavioural signs may be eased (9;10).  
Late start of dietary treatment will not alter the structural brain damage already 
present, but the biochemical changes, which occur in persons with PKU as a result of 
dietary intervention do have positive effects on the majority (7;9;11). 
1.1.1 History of PKU  
Phenylketonuria was first described in 1934 by the Norwegian doctor and scientist 
Asbjørn Følling. He found phenylketones in the urine of some mentally retarded 
children. He hypothesised that the symptoms were due to an inherited disease 
involving the metabolism of phenylalanine (2;12). This proved to be correct, and 
twenty years later Horst Bickel presented the first dietetic study from England, 
showing that a phenylalanine reduced diet lowered blood phenylalanine and relieved 
symptoms in PKU (13).  
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With treatment of PKU now available, it became important to screen babies for 
elevated phenylalanine (4). The first screening tools tested the babies’ urine for 
phenylketones at about three months of age. During the 1960’s blood screening 
became available. In Norway, newborn blood screening has been nationally available 
since 1975. Only one baby is known to have missed screening after this (2). During 
the last few decades mental retardation due to phenylketonuria has been almost 
eliminated in countries with well-running national screening programmes. Children 
are screened for PKU within a few days after birth, and if serum phenylalanine is 
above 400 µmol/L, dietary treatment is immediately started (1;2). 
1.1.2 The PKU diet  
The principles of the PKU diet are the same today as they were 50 years ago. The 
intake of phenylalanine is restricted to requirements for growth and individual 
tolerance (1;5). In keeping phe levels within therapeutic levels, the diet will be so 
restricted that the intake of protein, vitamins and minerals will be below human 
requirements if not otherwise substituted. According to Scriver & Kaufman the 
treatment is defined as a semi-synthetic diet, low in phenylalanine content and 
presumed to be adequate in other nutrients (1).  
To secure nutritional needs a protein substitute, devoid of phe, is given. The 
substitute is usually enriched with vitamins and minerals, and is taken with meals, at 
least three times a day (14). The intake of phe, or natural protein, is measured in 
milligrams (5). In order to maintain serum phe levels within the therapeutic range, 
most adults with PKU tolerate 500 – 1200 mg Phe per day (equivalent to 10 to 25 
grams of protein). The variation is mainly due to an individual degree of impaired 
phenylalanine hydroxylase activity (PAH) (1).  
In a mixed Western diet, where protein consumed derives from a mixture of animal, 
cereal and vegetable sources, about 5% of the total protein weight will be 
phenylalanine (5). In fruits and vegetables the phenylalanine content is lower than in 
cereal or animal protein; usually between 3 and 4 % of the protein weight is 
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phenylalanine (15). Therefore fruits and vegetables are preferred sources for natural 
protein in the diet. Products consisting mainly of fat, starch and sugar are used to 
meet energy requirements, together with special protein reduced products. The 
available special products are flour or baking mixes, bread, pasta, cereals and milk 
substitutes. The diet requires special preparation. Lists on phenylalanine content food 
and special recipes are used in calculating phe intake and preparing meals (16;17). 
1.1.3 PKU treatment 
The annual incidence of PKU is 1 in 12–13000 live births in Norway. On average this 
means about five new patients annually. In Europe the average incidence is about 1 in 
10000, varying from about 1 in 3000 in Turkey and 1 in 5000 in Ireland to less than 1 
in 100 000 in Finland (1;2).  
In Norway diagnosis and treatment of PKU is centralised to Rikshospitalet (2;18). 
Blood samples from about 58 000 newborns, in addition to routine blood tests from 
about 150 PKU patients on diet, are analysed every year for phenylalanine 
concentration. The diet is supervised by metabolic dietitians at Rikshospitalet. All 
patients with PKU born after 1970 in Norway are registered at the hospital. Patients 
born prior to 1970 are usually only registered if they are on diet or have followed 
dietary treatment at an earlier age. Of a total of about 160 patients older than 18 years 
of age, 70 were born in 1970 or before (personal communication from metabolic 
dietitian Åse Andresen Bradley at Rikshospitalet). 
Adult patients on diet have annual or biannual ambulatory consultations at the 
Medical Outpatient Department at Rikshospitalet, irrespective if treatment started 
after newborn screening or later. For the severely retarded patients treatment and 
follow-up is performed in cooperation with local practitioners and group home staff, 
without visits to the hospital.  
There is no exact cut-off level for when phenylalanine starts to be toxic, and 
treatment limits tend to differ somewhat between countries and metabolic centres 
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throughout the world. In addition it has been found that phe levels in the brain can be 
both higher or lower than the level measured in blood (1;6;7). Treatment levels for 
phenylalanine in serum are therefore mainly based on experience. The treatment 
levels have become more strict over time, especially for younger children and 
pregnant women with PKU. Consensus on optimal treatment levels is lacking, and in 
the United Kingdom and Germany the upper limits are graded according to age. In 
Norway the treatment recommendations for serum phe are uniform at all ages, the 
range is 120 – 400 µmol/L (18). This is about 2-6 times the normal non-PKU level. 
Individual consideration is taken in follow-up of adolescents and adults, and many 
adults on diet choose to have mean serum phenylalanine higher levels than 400 
µmol/L.  Up until the 1980’ies dietary treatment was usually stopped or relaxed in 
late childhood or adolescence. The current advice, in most Western countries and in 
Norway, is that dietary treatment should be lifelong (19-21). After childhood, as 
growth and building of body protein stores have come to a halt, the tolerance of 
dietary phenylalanine per kg bodyweight is reduced to maintenance levels. 
Measuring the blood phe level is the only practical biological marker for treatment 
adherence.  
1.1.4 Late treatment of PKU 
That late diet start could relieve symptoms in PKU, was first described by Bickel in 
the early 1950’ies (13). The first treatment of PKU was on a two year old girl, who 
showed striking behavioural and neurological response as phenylalanine in the blood 
was reduced to about 800 µmol/L. A blind provocation with phenylalanine resulted in 
return of head banging, restlessness and loss of eye contact.  
Results from this first trial and fifty years of clinical experience have proven the 
effects of dietary treatment. Dietary treatment for PKU in children diagnosed after 
newborn screening was never tried in a randomised controlled study, and today a 
randomised study would be judged as unethical (14).  
Randomised studies on late treatment of older children or adults are also lacking. 
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There was, however, a study in Norway during the 1980’ies, using an A-B-A design. 
The two subjects in this study acted as their own controls. After months on diet, 
period A, the subjects underwent a blind provocation, period B. Caretakers were 
blinded in relation to the addition of phenylalanine to the previously phenylalanine 
free protein substitute. Period B lasted until symptoms of self-mutilation reappeared 
after five months, after wich dietary treatment was resumed for another 3 months of 
observation, the second period A. This trial showed that positive effects were 
apparent during treatment, and disappeared when normal protein intake was resumed. 
A report was published for one of the patients in 1994 (22). Details of the diet were 
documented by Motzfeldt, but never published (23). Both subjects have since been on 
permanent diet.   
Later Fitzgerald et al planned a similar study on several patients in England (24). 
However, treatment effects were so positive for most subjects that provocation was 
deemed unethical. It was decided that treatment should be continued on a permanent 
basis for four out of five subjects, even if this weakened the scientific value of the 
study. Most other studies on adults with late treatment have been case studies, also 
without provocation (9;25;26). 
1.2 Background for this study 
Today most people with PKU, in the Western world, are treated from the newborn 
period, and PKU no longer leads to mental retardation (1;11). Of those who are 
retarded today, the majority are adults, born before newborn screening programmes 
were available. A few younger subjects may have been lost to screening or are born 
in countries where screening and dietary treatment are unavailable. Therefore dietary 
treatment of adults in need of special support will continue to be necessary. 
Several trials and case studies have showed the effect of implementation of  a low-
phenylalanine diet in adult life on neurological and behavioural abnormalities 
(9;10;24-29). The improvements are often obvious both to the patient and caregivers. 
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The most important findings are reduction in self-mutilation, screaming and 
aggressive behaviour. Alertness and communication skills may be enhanced, and the 
musty odour will disappear. Most studies on late treated patients describe the 
neurological or neuropsychological changes while the nutritional or dietary aspects of 
the treatment are not discussed, apart from reporting that the dietary principles are 
important (9;24;25). The intention of this study is to focus on the nutritional or 
dietary aspects. 
Literature on how patients with PKU and their caregivers translate the advice and 
prescriptions from doctors and dietitians into an everyday diet is lacking. The 
principles of how the diet should be composed to lower toxic phenylalanine levels are 
known (5). Most available studies report dietary effects on serum phe, without giving 
details on how the diet is composed. A few studies on diet and nutrition are available, 
mainly for children and adolescents treated after newborn screening (30-33). Most 
studies look at single nutrients such as protein (34-36), iron (37) or fat (38;39) in the 
PKU diet. There are studies postulating special nutrient metabolism in PKU and 
deficiencies or shortcomings of the diet (40-43). Most studies do not relate their 
findings to the food products chosen or total nutrient intake. This makes it more 
difficult to evaluate the need for changes in the composition of the diet, and what 
special advice patients need in order to manage the treatment.  
In the present study the diet of one small subgroup of PKU, mentally retarded adults, 
is described. Perhaps the results reported can give further knowledge which will 
improve the diet and lead to better follow-up for people who need this special and 
restricted diet in order to achieve a better quality of life. 
 
“It has been hard, and I am still not used to it. But it is fun to manage 
the diet and notice that it is helping me.” (Subject) 
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2. Aims and hypotheses 
The objective of this study was to analyse the composition of the dietary intake and 
describe how the restricted diet is managed by adults with PKU and brain damage 
due to late diagnosis.  
The study aims may be expressed more specifically with the following questions.  
• Can adults on a PKU diet follow the same nutritional recommendations as the 
general population, and are persons with mild to moderate mental retardation 
able to manage the diet?  
• Does the diet result in satisfactory nutritional status for a subgroup of adults 
with late diagnosis of PKU?  
• Is the diet effective in reducing serum phenylalanine and is it associated with 
improvements of symptoms and clinical signs of PKU? 
• How did patients and caregivers describe the strains of adhering to the diet? 
• Is it possible to point out or define a minimum of prerequisites necessary for 
managing the diet of adults with mental retardation and PKU? 
 
In order to answer these questions the following hypotheses will be tested.  
1. Adults with brain damage due to late diagnosis of PKU will:  
a. have a nutrient intake in compliance with the Nordic Nutrition 
Recommendations 2004 (44);  
b. have a satisfactory nutritional status, measured by BMI and standard 
biochemical markers;  
c. have a mean serum phenylalanine complying to Norwegian treatment 
standards.  
2. The degree of mental retardation or need for support will have no influence on 
dietary intake, markers for nutritional status, average phenylalanine levels or 
dietary adherence. 
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3. Ethical considerations 
The majority of the subjects in this study were unable to give consent according to 
the Declaration of Helsinki (45). In accordance with international ethical standards 
and Norwegian legislation, medical research studies implying blood samples or other 
major interventions in the daily lives of people unable to give informed consent, have 
to be considered necessary for promoting health in order to be recommended. 
Recommendations for evaluation studies or descriptive studies on people or groups of 
people without full ability to understand and give consent are in principle more 
difficult to obtain than studies involving testing of drug therapy (46-48;48). Close 
relatives, caregivers or legal guardians can only give advice and not consent on 
behalf of their wards (48). This study was designed to meet the Norwegian ethical 
and legal standards (48-50). To minimise the burden on persons without the ability to 
consent, the blood tests taken in this study were restricted to those regularly taken at 
clinical controls for follow-up of PKU treatment.  
All invited participants had some degree of learning disability or mental retardation; 
hence information and the form for consent had to be both easily read and reasonably 
short (Appendix 4 and 5). The instructions and information had to fulfil the standards 
of the Declaration of Helsinki (45). Thus two sets of information were distributed, 
one for the participants who could give consent themselves, and one for the 
caregivers, relatives and/or legal guardians who needed information and would be 
involved in the study (Appendix 5 and 6). 
3.1 Approvals and recommendations  
The study was recommended by the Regional Committee for Medical Research 
Ethics on the 14th of March 2006 (Appendix 1). Approval was granted provided that 
it would interfere minimally with the everyday life of subjects unable to give 
informed consent (14 of 21 participants).  
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In order to use blood samples for research purposes from these patients, it was 
necessary to apply for a bio-bank consent according to the Norwegian Bio-bank Act 
(49). This authorisation was given 3rd of April 2006 (Appendix 2).  
As the author and the main tutor are both employed at Rikshospitalet, the study was 
reported to the commissioner for privacy protection (personvernombudet) at the hospital. 
Approval was given on the 8th of March 2006 (Appendix 3). 
 
 
“He has had bad periods with aggressive behaviour also when on diet, 
especially during holidays. Some improvement has come because we’re 
better in managing the diet, other changes are due to better routines in 
the group home.”  (Caregiver) 
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4. Subjects and methods 
4.1 The sample 
In this study all adult PKU patients in Norway, born prior to 1988, known to have 
mental retardation and following a diet for PKU were invited to participate.  
• Criteria for inclusion: People with PKU over 18 years of age, having mild to 
profound mental retardation, and adhering to PKU treatment according to the 
definition beneath.  
• Criteria for exclusion: People with PKU over 18 years of age, without mental 
retardation, or not adhering to PKU treatment according to the definition 
beneath. 
For inclusion in this study adherence to treatment had to be defined. People were 
defined as adherent if they claimed to be following a PKU diet and if Rikshospitalet 
received blood samples for routine control of serum phenylalanine at least 2-4 times a 
year. In addition, all participants should have been in contact with the Centre for Rare 
Disorders to receive advice or information on living with PKU.  
The total sample consisted of 27 persons; 26 were diagnosed late (age at diagnosis 
was 1 to 30 years of age). One subject with mild mental retardation of unknown 
origin was also invited. This person was diagnosed with PKU and treated after 
neonatal screening. Of the 27 invitations distributed, 21 positive answers were 
returned, resulting in a response rate of 78%. Table 1 shows the response rate in the 
different groups of eligible participants.  
The participants in the present study had been on diet for at least one year. Treatment 
had been judged as beneficial and was maintained on a permanent basis at the time of 
the study. For one patient, however, evaluation of one years treatment showed both 
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positive and negative behavioural effects. Decision on further dietary treatment on a 
permanent basis was scheduled to take place a couple of months after this study.  
 
 
 
Table 1: Description of participants 
Group A  Group B  Men Women Men Women Total 
Eligible 3 8 9 7 27 
Participants 1 6 7 7 21 
 
 
4.1.1 Subgrouping of sample 
The participants were divided into two groups, according to everyday function, see 
table 1.  
• Group A: Subjects managed most skills needed for independent and everyday 
self-care, all had adequate communication skills. The subjects received limited 
support from parents and/or community. They lived alone, with their spouse or 
with parents. The degree of mental retardation in group A corresponded to 
mild or moderate mental retardation in the International Classification of 
Diseases (ICD10) by The World Health Organisation (51). Persons belonging 
to this group were able to give informed consent (45). A total of eleven were 
invited, and seven consented to participate. 
• Group B: Subjects lived in staffed community group homes and needed 
continuous support. Some had simple verbal skills. The degree of mental 
retardation in subjects in group B corresponds to severe or profound mental 
retardation in the ICD10 classification (51). Nobody in this group was able to 
give informed consent. In group B fourteen out of sixteen participated. Two 
group homes had each two residents with PKU, giving a total of twelve group 
homes represented in the study. 
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4.2 Study design 
The study was an observational cross-sectional study on adult patients with PKU.  
Together with the invitation and form for consenting to participation (Appendix 4), 
the subjects received two information letters, one aimed at the participants themselves 
and one for relatives or caregivers, group home staff or legal guardians (Appendix 5 
and 6). Additional information regarding the study was given on request by 
telephone. A reminder was sent after 10 days to those who had not responded. Nine 
group homes were contacted by telephone to secure that the information had been 
considered by responsible staff.  
Data were collected by a semistructured interview, a four-day weighed food 
recording, blood samples and hospital patient records.   
Seven subjects were interviewed in connection with ambulatory consultation at 
Rikshospitalet. They received information on food registration and took blood 
samples at the same visit. For the additional 14 subjects, the author visited the group 
homes for interviewing, information on food registration and blood sampling. 
4.2.1 Semistructured interview 
The interview was a semistructured survey, prepared and administered by the author 
(Appendix 7). It was designed with an interview guide based on the model of Monica 
Dalen (52). Prior to the study the interview was tested on colleagues for 
determination of specificity, comprehension and time required.  
Survey topics were socioeconomic background, history of diagnosis, organisation of 
the diet work, phe-tolerance and treatment effects. 
All subjects in group A were interviewed personally, and for subjects in group B 
caretakers were interviewed. Relatives, mostly mothers, gave additional information 
related to eight subjects, four from each group. 
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The semistructured interview functioned mainly as a qualitative method in order to 
gain better insight and understanding of the subject’s personal experiences (52;53). In 
this study, interview was used as a supplement to quantitative methods. It was known 
that some participants in the study might have difficulties in reading and answering 
written surveys. The interview process gave the subjects the possibility of answering 
in their own words and also to have questions reformulated and explained in different 
ways.  
Interpretation and analysis of the interviews were done in two different ways. 
Questions with fixed answers were quantified and could be used in statistical 
analyses. Other questions were open, and some were categorized and ordered into 
qualitative groups and used in frequency distributions. 
Reports on clinical effect or changes related to dietary treatment were collected 
retrospectively by means of interview or hospital patient records.  
4.2.2 Registration of food intake for four days  
Intake of food and drink was registered in four subsequent days, within two weeks 
after the interview. Verbal and written information was given on how to measure and 
document food intake (Appendix 8). Intake was recorded in a booklet designed 
especially for this study (Appendix 9). This method was chosen because the 
participants and their helpers already were accustomed to weighing and measuring 
food. Taking a dietary history or 24-hour recall was deemed more complicated as the 
subjects in group B usually had at least two different caregivers responsible for 
preparing and serving meals during the day. Caregivers were responsible for all 
recordings in group B. Four subjects in group A received extra support from family 
or community workers in recording their food intake. The remaining three subjects 
had contact with the author at least once a day during the recording period. All 
participants were contacted by telephone at least once during the registration, and the 
author could be reached by telephone at any time.  
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Food was weighed on digital scales, with 1 gram increments. Drinks were weighed or 
measured in decilitres. All but two subjects were used to weighing food, either for 
measuring prescribed amounts of natural foods and protein substitute, or as a method 
in cooking and baking. The registration booklets were returned by mail, in pre-
stamped envelopes. 
Food and drink registration was recorded and calculated in a Norwegian nutrient 
calculation software “Mat på data 4a” (54). This programme uses the official 
Norwegian food composition tables from 2001 (55). The food composition tables 
were supplied with data on special dietary products, information having been 
collected from producers. Phenylalanine content was calculated according to 
Norwegian PKU lists (16). The lists are based on the average amino acid distribution 
of protein in food products and official analyses from different countries and they are 
adjusted for the protein content of Norwegian food products (55).  
One subject used an unfortified protein substitute and had to take additional 
supplements of vitamins and minerals. These supplements were calculated as part of 
the protein substitute. Vitamin B12 content in food was not included in the program 
“Mat på data”, thus only vitamin B12 contribution from protein substitutes were 
calculated. 
Intake of fruit and vegetables was calculated as the total intake of juice, fruit, berries 
and vegetables. Potatoes, potato products and dried legumes were not included, as 
they contain more protein and are used in a different way in the diet (16;17). This is 
in contrast to the general Norwegian dietary recommendations where potatoes are 
included in the recommendation of at least five portions or 750 g/d fruit and 
vegetable intake (56). 
4.2.3 Blood sampling and analyses 
Eight subjects had blood samples taken at the laboratory at Rikshospitalet. The eleven 
others had blood samples taken at a local hospital or laboratory. For these subjects 
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information on blood sampling was distributed at visits to the group homes. This 
consisted of an information letter for the local practitioners and/or laboratory staff, 
two requisition forms and an instruction on handling the blood samples (Appendix 
10-12). The information was prepared in cooperation with senior consultant Per 
Mathisen, MD, responsible for follow-up of adult PKU patients at the Medical 
Outpatient Department, and senior consultant Berit Woldseth, MD, Department of 
Medical Biochemistry, both Rikshospitalet.  
All blood samples were taken as a part of the clinical follow-up program for the 
subjects. Requisitions were signed by doctor Per Mathisen, and copies of the answers 
were forwarded to the author. As the majority of subjects could not give consent, 
secondary blood samples could only be taken if deemed medically necessary at the 
time. As a result some blood samples were lost, due to improper procedures or 
because they were unsuccessfully analysed. For two subjects, venous drawing of 
blood could only be done in anaesthesia, and this was only done when requested for 
medical reasons and dental care.  
Missing data from blood analyses are due to these limitations. 
Amino acids 
Amino acids in blood were analysed at the Department of Medical Biochemistry at 
Rikshospitalet. The blood was drawn into heparin glasses after overnight fasting. It 
was then centrifuged and frozen within thirty minutes. Amino acids were analysed by 
ion exchange chromatography with ninhydrine colouring on an Amino Acid Analyser 
Biochrom 30, from Biochrom Ltd, Cambridge, United Kingdom (personal 
communication from Berit Woldseth).  
Other blood samples 
Blood samples for the amino acid test, iron status, blood lipids, renal function, 
albumin, prealbumin, magnesium, zinc, vitamin B12 and folic acid were drawn 
simultaneously. All samples were planned to be analysed at the Department of 
 31
Medical Biochemistry at Rikshospitalet; however for two subjects the blood samples, 
apart from the amino acid analyses, were analysed at local hospitals. Analyses were 
done according to standard procedures at the laboratory, described in The Laboratory 
Handbook (57). For most analyses in this study the laboratory used accredited 
methods.  
Routine phenylalanine tests 
Routine tests for serum phenylalanine in capillary blood, obtained by finger pricking, 
were analysed by the Neonatal Screening Laboratory at Rikshospitalet. After 
overnight fasting sampling was done by the parents, nurses in group homes or by 
local laboratory staff. Microtainers with 0.5 ml blood were sent by mail to the 
Screening Laboratory. Phenylalanine in the serum was determined fluorimetrically 
after enhancement of the fluorescence by a phenylalanine-ninhydrin reaction in the 
presence of a peptide, leucylalanine. This is a specific and sensitive method, first 
described by M. W. McCaman in 1962 (58)  
4.2.4 Data on treatment history 
Retrospective data on blood phenylalanine levels and treatment history were found in 
hospital charts, or communicated via the interviews.   
4.2.5 Statistics  
Descriptive statistics were done on socioeconomic background, diagnosis, 
anthropometrics and treatment history.  
Statistical analyses were done on parameters from interview, blood tests and food 
intake and the following methods were used. 
For categorical data: frequency distributions and cross-tabulations.   
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For continuous data: descriptive statistics (median, quartiles of the median, range, 
mean and standard deviation), Mann-Whitney U-test, Spearman’s rho  rank 
correlation. 
The study was done on a small number of participants, and there was great variability 
between subjects. Therefore the median and the inter-quartile range were chosen 
rather than the mean to describe variability in the total sample and when group A and 
B were described as separate entities (59;60).  
Statistical calculations and analyses were performed on Statistical Package for the 
Social Sciences (SPSS), version 13.0 for Windows. 
4.2.6 Economy 
All mail to or from participants was paid by the Centre for Rare Disorders at 
Rikshospitalet. The visits from the author to group homes were followed by meetings 
with the staff, and these were also financed by the Centre for Rare Disorders.  
As the study was organised in connection with ordinary outpatient follow-up, blood 
tests and analyses were paid through the Norwegian social security system. 
4.2.7 Feed-back to participants 
After the food registrations were calculated and evaluated, the subjects or their 
caregivers received individual feed-back and dietary advice from the author. Subjects 
in need of sustained dietary changes were referred to metabolic dietitian for further 
advice.    
Treatment changes indicated by blood test results were handled by dr. Per Mathisen 
or the local general practitioner. 
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5. Results 
5.1 Subject characteristics 
All subjects in group A (n=7) managed everyday meals, Table 2. Most of them had 
difficulties in reading recipes; all had difficulties in planning and organising their 
diet. Three received daily dietary support for controlling amounts, preparation or 
planning of meals and for acquisition of special food products and protein substitute. 
Two lived in the same house as their parents, but in separate apartments. Three were 
married, but the spouses did not have sufficient resources to give substantial support 
in the dietary work.  
Table 2: Background data on participants 
 Group A n=7 
Group B 
n=14 
Ability to consent Yes No  
Function in 
everyday life 
Independent living. 
Limited support from 
family or society. 
Living in staffed 
group homes. 
Continuous support.  
 
 
In group B (n=14) everyone was dependent on the staff for preparation and serving of 
meals, Table 2. Eight subjects needed soft textured food, due to teeth and denture 
problems or an inability to chew. Two subjects were unable to eat or drink without 
help, and another four needed some assistance during meals. Four subjects used 
wheelchairs; four more had restricted walking function. 
Some could make restricted choices related to meals, for example in choosing 
between two alternatives like: coffee or tea, PKU-milk or juice. Most subjects in 
group B were unable to differentiate their own food from food belonging to others, 
and “stealing” or snatching accessible food was a problem in some group homes. 
Two subjects had very selective food preferences, making variation and presentation 
of new food difficult. Seven persons took initiative to obtain food or drink (mainly 
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coffee) without being encouraged in advance, and four had some verbal 
communication skills.  
 Table 3: Treatment history  
  Group A Group B Total P
 
 
N 7 14 21 
 
 
Mean (SD) 39.3 (9.4) 50.1 (7.5) 46.5 (9.5)  
Median (Q1-Q3) 42 (28 – 48) 49 (45 – 53.5) 48 (42 – 51.5) 0.02 
Age, years 
Min-max 26 – 51 36 – 66 26 – 66  
N 7 12 19 
 
 
 
Mean (SD) 2.4 (1.2) 6.6 (8.3) 5.1 (6.8)  
Median (Q1-Q3) 2.5 (2 – 3) 4 (1.6 –  9.8) 2.5 (2 – 5) 0.43 
Age at 
diagnosis, 
years 
Min-max 0.1 – 4 1 – 30 0.1 – 30  
N 7 14 21 
 
 
 
Mean (SD) 8.5 (17) 27.9 (17.2) 21.4 (19.2)  
Median (Q1-Q3) 2.5 (2 – 3) 36 (3.8 – 41.8) 26 (2.5 – 41.5) 0.07 
Age at first 
treatment, 
years 
Min-max 0.1 – 47 1.5 – 45 0.1 – 47  
N 7 14 21 
 
 
Mean (SD) 20.8 (13.5) 15.7 (11.7) 17.4 (12.2)  
Median (Q1-Q3) 25 (2.5 – 31) 10 (9 – 22) 18 (9 – 26) 0.32 
Current diet 
period 
lasted,  
years Min-max 1 – 35 1.5 – 41 1 – 41   
N 7 14 21 
 
 
 
Mean (SD) 1772 (423) 1669 (320) 1704 (350)  
Median (Q1-Q3) 1540(1500-2376) 1591(1521-1885) 1591(1497-1882) 0.91 
s-phe prior 
to treatment, 
µmol/L 
Min-max 1471 – 2400 1131 – 2468 1131 – 2468  
N 7 14 21 
 
 
 
Mean (SD) 642 (254) 489 (122) 540 (186)  
Median (Q1-Q3) 596 (456 – 795) 432 (382 – 633) 472 (417 – 625) 0.08 
Mean s-phe 
one year 
prior to 
study, 
µmol/L Min-max 432 – 1143 352 – 717 352 – 1143  
N 7 14 21 
 
 
 
Mean (SD) 665 (336) 474 (158) 538 (242)  
Median (Q1-Q3) 600 (389 – 853) 505 (336 – 621) 542 (373 – 635) 0.17 
s-phe at 
study, 
µmol/L 
Min-max 293 – 1310 146-731 146-1310  
The Mann-Whitney U-test is used for differences between group A and B  
P = p-value for difference between group medians 
Q1 = first quartile or 25th percentile, Q3 = third quartile or 75th percentile 
 
 
Subjects in group A were significantly younger than subjects in group B, Table 3. 
The age at diagnosis or first treatment, serum phenylalanine at diagnosis or one year 
prior to the study, did not differ significantly between the groups.  
Each individual tended to have fairly stable values of serum phenylalanine; single 
tests could, however, be higher or lower than the personal average. Rank correlation 
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for mean serum phe one year prior to study and serum phe at the study (just before or 
after the food recording) gave a Spearman’s rho correlation of 0.83 (p<0.01), Figure 
1. The subjects maintained the same mean serum phe levels also over a longer period, 
with a Spearman’s rho correlation of 0.82 (p<0.01) between serum phe levels one 
year prior to study and  two years prior to the study.  
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Figure 1: Association between serum phe at the study
and mean serum phe level one year prior to the study
 
 
 
 
 
 
 
 
 
 
5.1.1 Socioeconomic background 
All subjects received social security benefits for the disabled. All but one received 
extra welfare money for diet expenses.  
Six in group A and one in group B had part time work, all received some supervision. 
Three of these were employed in sheltered workshops. Ten subjects in group B 
attended day-care units for the mentally retarded. In workshops and day-care units, 
dietary needs were taken into consideration at mealtimes.  
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Ten persons, three in group A and seven in group B, took part in afternoon leisure 
activities at least once a week. In group A three subjects had no regular or organised 
leisure activities. 
5.2 Effect of treatment     
Reports on changes in selected symptoms and signs related to diet and reduction of s-
phe levels were collected retrospectively from the interviews. The frequencies of the 
most common variables for clinical effect in late treated patients with PKU are listed 
in Table 4. In addition improvement in neurological signs like better balance and gait, 
reduced tremor or spasticity were reported for ten (47.7%) in the total sample; or 
three (42.9%) in Group A and seven (50%) in group B.  
 
 
 
 
 
 
 Table 4:  Reported effects after starting dietary treatment  
 A (n=7) B (n=14) Total (n=21) 
Self-mutilationa 1 (14.3%) 10 (71.4%) 11 (52.4%) 
Agititationb 2 (28.6%) 12 (85.7%) 14 (66.7%) 
Alertnessc 6 (85.7%) 8 (57.1%) 14 (66.7%) 
Haird 3 (42.9%) 11 (78.6%) 14 (66.7%) 
Odoure 3 (42.9%) 11 (78.6%) 14 (66.7%) 
a reduction in self-mutilation and self stimulating behaviour 
b reduced pacing, screaming and hitting others 
c improved awareness of surroundings, attention and concentration 
d darkening of hair  
e musty body odour disappeared 
 
Other treatment effects were better skills in communication, defined here as own 
speech or understanding, verbal and non-verbal response to instructions or signs of 
recognition/differentiation between people. Treatment effects resulting in increased 
social participation and appreciation of contact with others were also reported. 
Communication skills and social participation are counted together as the terms 
seemed closely related when reported from informants. Positive effects were reported 
for fourteen (66.7%) subjects; five (71.4%) in group A and nine (64.3%) in group B. 
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Increased initiative, defined as starting activities or making requests without 
prompting from others, or uttering signs of likes and dislikes, were reported for six 
(85.7%) in group A and 7 (50%) in group B, or for 13 (61.9%) in the total sample. 
Subjects in group A reported personal experiences after having started or resumed 
treatment as adults. Subjective effects of treatment were reported as better sleep at 
night by five persons (71.4%) and the same number meant that adherence increased 
their self-confidence or mastering abilities. Three (42.9%) reported that they had less 
anxiety and psychiatric problems when on diet. 
5.3 Support and diet organisation 
Information about support, effectiveness of everyday routines and the experience of 
problems in adherence were categorized from the interviews. The subjects in group A 
who did not receive regular assistance from community or parents, had fewer 
working routines for food preparation and for acquisition of special foods and protein 
substitute. The subjects in group A  expressed practical and emotional problems in 
adhering to the diet. Three subjects in group B lacked effective routines or because 
written procedures and menu lists were lacking not followed, Figure 2. No subject in 
group A felt that following the diet was problem free, and nobody managed to keep 
routines as stringent as those living in group homes. 
The effectiveness of dietary routines and the degree of experienced difficulties in 
adhering to diet was associated with the subject’s individual average serum phe 
levels. Figure 3 shows that subjects with serum phe below the median for the total 
group, tended to have more effective routines and experienced fewer problems than 
subjects with average serum phe over the median.  
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“I wished there was another person on diet close to where I live, you 
need to talk to somebody.” (Subject) 
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fig. 3b: s-phe >/=472 µmol/Lfig. 3a: s-phe <472µmol
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5.4 Blood samples 
Blood tests were collected from 17 subjects. Amino acids in serum were analysed for 
15 subjects.  Results from amino acid analyses are shown in Appendix table 1. 
As anticipated, all subjects had high phenylalanine. Apart from this only small 
discrepancies were observed, mostly due to mistakes in handling: in some samples 
the time before centrifugation or freezing might have been too long and for two 
subjects serum was used instead of heparin blood.  
A high glycine value was seen in two subjects, but valine was normal for all 15 
subjects.  
Tyrosine was in the normal range (28 to 76 µmol/L) for all but one who had 100 
µmol/L. This person took a protein substitute based only on essential or large neutral 
amino acids (LNAA). This substitute contained higher amounts of tyrosine and 
tryptophan than other substitutes.  
Results from other blood tests analyses are shown in Appendix table 2.  
Apart from folate, most results were within normal limits for age and sex. Folate in 
erythrocytes was beyond upper normal limit for the laboratory (1140 nmol/L) for 10 
of 13 subjects. For serum folate 13 of 15 analyses were beyond the upper normal 
limit (27 nmol/L). Eight had values over the highest measurable value (54.4 nmol/L), 
Figure 4. Folate in serum correlated significantly to folate intake; Spearman’s rho 
correlation 0.59 (p=0.02).  
Vitamin B12 levels were generally high, five out of 17 exceeding the upper normal 
limit (10 pmol/L). One person had low serum vitamin B12  (110 pmol/L).  
Iron, ferritin, transferrin and transferrin saturation in plasma were generally in the low 
normal range. All subjects had normal levels of haemoglobin. One person had signs 
of iron deficiency: ferritin 9 µg/L (WHO cut-off value <15µg/L), iron 7 µmol/L 
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(normal range 9-34 µmol/L) (44). Another subject had a low ferritin 11 µg/L (WHO 
cut-off value <15µg/L), but other parameters were in the lower normal range. 
 
 Figure 4: Folate in erythrocytes and serum 
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Albumin was normal for everyone, but prealbumin was just below the normal limit 
for four subjects, and unsuccessfully analysed for one. One female had a low 
prealbumin of 0.16 g/L (normal range 0.23 – 0.39 g/L). 
Median total cholesterol for the total sample was 4.6 mmol/L. In group A, one person 
had a total cholesterol over 5 mmol/L (6.5 mmol/L), this person also had high serum 
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triglycerides. In group B three subjects had a total cholesterol over 5 mmol/L (5.5, 
7.8 and 5.7 mmol/L), one also had high triglycerides. 
5.5 Intake of energy and nutrients 
The food registrations were done for 19 subjects. Two subjects in group B did not 
take part in the registrations due to lacking staff resources. The registrations were 
marked by the subjects or their helpers as reflecting habitual intake on days with 
usual activities. One person in group A took part in a social gathering in the recording 
period; all food was recorded and was included in the calculations. In group B one 
subject became ill during the recording period and one day of food registration was 
subsequently omitted from calculations for this subject.  
There were no significant differences between group A and B in median daily intake 
of energy, macronutrients, dietary fibre or fruit and vegetables, Table 5. Neither were 
there any significant differences between group A and B when intake was expressed 
as energy density, energy % (E%), Table 6. 
5.5.1 Energy intake and expenditure 
The subjects had a median energy intake of 8.8 MJ/day, ranging from 6.4 MJ to 13.7 
MJ. Goldberg’s cut-off limits to identify under-recording of energy intake were used 
to validate the food registrations (61). Estimations of basal metabolic rate (BMR), 
based on height, weight, gender and age, were done in order to calculate the physical 
activity levels (PAL) from reported energy intake. The equations of Schofield and 
World Health Organisation were used to estimate BMR (62). The mean PAL value 
for the 19 registrations in this study was 1.39, just above the cut-off limit of 1.37 for 
groups of twenty subjects given by Goldberg (61). The median PAL was also 1.39 
with an interquartile range (Q1-Q3) of 1.27 – 1.47, and a total range of 1.17 – 1.75.  
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 Table 5: Intake of main nutrients, added sugar, dietary fibre, fruit and 
vegetables 
  Group A Group B Total 
 N 7 12 19 
 
P 
Mean (SD) 8.6 (0.7) 9.8 (2.3) 9.4 (1.9)  
Median (Q1-Q3) 8.2 (8.0 – 9.1) 9.3 (8.0 – 12.2) 8.8 (8.0 – 10.1) 0.43 Energy, MJ/d 
Min-max 7.9 – 10 6.4 – 13.7 6.4 – 13.7  
Mean (SD) 67.1 (18.6) 79.9 (11.4) 75.2 (15.4)  
Median (Q1-Q3) 72 (54 – 81) 79 (70 – 87) 77 (68 – 85) 0.17 Protein, g/d 
Min-max 33 – 87 65 – 106 33 – 106   
Mean (SD) 58.0 (13.8) 71.0 (20.3) 66.2 (18.9)  
Median (Q1-Q3) 65 (47 – 68) 73 (52 – 85) 65 (48 – 78) 0.20 Fat, g/d 
Min-max 37 – 76 42 – 102 37 – 102   
Mean (SD) 20.7 (8.1) 25.1 (8.8) 23.5 (8.6)  
Median (Q1-Q3) 21 (14 – 23) 26 (18 – 31) 22 (17 – 30) 0.26 SFA, g/d 
Min-max 12 – 36 12 – 39 12 – 39   
Mean (SD) 12.3 (3.7) 15.9 (6.7) 14.5 (5.9)  
Median (Q1-Q3) 12 (10 – 16) 17 (10 – 21) 14(10 – 18) 0.34 MUFA, g/d 
Min-max 6 – 17 7 – 28 6 – 28   
Mean (SD) 15.6 (6.9) 19.9 (5.9) 18.3 (6.5)  
Median (Q1-Q3) 15 (11 – 21) 20 (15 – 25) 20 (13 – 25) 0.20 PUFA, g/d 
Min-max 5 – 25.3 8 – 28 5 – 28   
Mean (SD) 314.8 (51.7) 341.8 (90.1) 331.8 (77.6)  
Median (Q1-Q3) 320 (275 – 333) 321 (271 – 414) 320 (275 – 411) 0.65 
Carbo-
hydrates, 
g/d Min-max 247 – 411 212 – 494 212 – 494  
Mean (SD) 85.3 (57.8) 84.4 (42.3) 84.7 (47.0)  
Median (Q1-Q3) 73 (34 – 132) 90 (41 – 121) 73 (38 – 123) 0.26 
Added  
sugar, g/d 
Min-max 9 -179 23 – 144 9 – 179   
Mean (SD) 14.7 (6.8) 18.3 (8.4) 17.0 (7.9)  
Median (Q1-Q3) 12 (10 – 21) 16 (13 – 23) 16 (11 – 21) 1.00 Fibre, g/d 
Min-max 9 – 27 8 – 38 8 – 38   
Mean (SD) 382.1(338.9) 551.8 (420.5) 489.3 (39.7)  
Median (Q1-Q3) 339 (137 – 575) 435 (195 – 848) 369 (147 – 706) 0.30 
Fruit &  
vegetables, 
g/d Min-max 71 – 1042 120 – 1361 71 – 1361   
The Mann-Whitney U-test is used for differences between group A and B  
P = p-values for difference between group medians 
Q1 = first quartile or 25th percentile, Q3 = third quartile or 75th percentile 
Fruit and vegetables = fruit, berries, juice and vegetables. 
 
The seven men had registered a median intake of 11.9 MJ/d (Q1-Q3: 8.8 – 12.4 
MJ/d). The twelve women had a median intake of 8.4 MJ/d (Q1-Q3: 7.9 – 9 MJ/d). 
This gave a significant difference on Mann-Whitney test for energy intake between 
the sexes (p = 0.01). Also the difference in energy % from added sugar was 
significant between genders, with a median intake for men of 15 E%, and 12.5 E% 
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for women (p = 0.03). Differences between the sexes in intake of energy, fat or fruit 
and vegetables were not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Intake, as percent of energy 
  Group A Group B Total 
 N 7 12 19 
 
P 
Mean (SD) 13.6 (4.2) 14.3 (2.8) 14.1 (3.3)  
Median (Q1-Q3) 14 (12 – 17) 15 (11.8 – 15.8) 14 (12 – 16) 0.84 Energy % from protein 
Min-max 6 – 19 10 – 20 6 – 20   
Mean (SD) 24.7 (6.1) 26.7 (4.1) 26 (4.8)  
Median (Q1-Q3) 24 (20 – 28) 27 (23.3 – 30.3) 26 (21 – 28) 0.38 
Energy % 
from fat 
Min-max 17 – 35 21 – 33 17 – 35   
Mean (SD) 8.7 (3.9) 9.3 (2.4) 9.1 (3.0)  
Median (Q1-Q3) 8 (6 – 9) 9 (8 – 10) 9 (7 – 10) 0.30 Energy % SFA 
Min-max 5 – 17 5 – 14 5 – 17   
Mean (SD) 5.3 (1.6) 6.0 (2.0) 5.7 (1.9)  
Median (Q1-Q3) 5 (4 – 6) 7 (4.3 – 7.8) 6 (4 – 7) 0.43 
Energy % 
MUFA 
Min-max 3 – 8 3 – 9 3 – 9  
Mean (SD) 6.6 (2.9) 7.4 (1.8) 7.1 (2.2)  
Median (Q1-Q3) 6 (5 – 9) 8 (6 – 8.8) 7 (6 – 9) 0.43 Energy % PUFA 
Min-max 2 – 11 4 – 10 2 – 11  
Mean (SD) 61.7 (6.0) 59.0 (4.1) 60 (4.9)  
Median (Q1-Q3) 64 (55 – 65) 59 (56.3 – 62) 59 (56 – 65) 0.34 
Energy %, 
carbo-
hydrate Min-max 53 – 70 53 – 66 53 – 70  
Mean (SD) 16.3 (9.9) 14.2 (5.9) 15 (7.4)  
Median (Q1-Q3) 15 (7 – 25) 15 (8.8 – 19.5) 15 (15 – 25) 0.59 Energy % added sugar 
Min-max 2 – 31 5 – 24 2 – 31  
Mean (SD) 1.7 (0.9) 1.9 (0.7) 1.8 (0.7)  
Median (Q1-Q3) 1.4 (1.0 – 2.7) 1.7 (1.3 – 2.3) 1.7 (1.3 – 2.4) 0.48 Fiber g/MJ 
Min-max 0.9 – 3.2 1 – 3.4 0.9 – 3.4  
The Mann-Whitney U-test is used for differences between group A and B  
P = p-values for difference between group medians 
Q1 = first quartile or 25th percentile, Q3 = third quartile or 75th percentile 
All participants led a sedentary life; only two male subjects had some regular 
physical activity by walking. Most subjects (16 of 21), had BMI>25, and could be 
defined as overweight, Table 7. Five were obese with BMI>30. None were 
underweight, the lowest BMI was 20.2. There was no significant association between 
BMI and sex, age, intake of nutrients or between group A and B. 
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Table 7: Subjects’ Body mass index (BMI) 
  Group A Group B Total 
 N 7 14 21 
 
P 
Mean (SD) 28.0 (6.4) 27.3 (4.1) 27.5 (4.8)  
Median (Q1-Q3) 28.0 (20.9-33.1) 27.5 (24.6-30.2) 28.0 (24.1-30.4) 0.91 BMI, kg/m2 
Min-max 20.4 – 38.5 20.2 – 34 20.2 – 38.5  
The Mann-Whitney U-test is used for differences between group A and B  
P = p-values for difference between group medians 
Q1 = first quartile or 25th percentile, Q3 = third quartile or 75th percentile 
 
5.5.2 Protein and phenylalanine intake 
The median total protein intake (from natural foods and substitute) was 1.02 g/kg for 
group A and 1.00 g/kg for group B, see Table 8. All subjects but one had a protein 
intake above the FAO/WHO recommendations of 0.75 g/kg (44). 
The proportion of natural protein to total protein intake was low, about 25% for the 
total sample. Subjects in group A obtained 25 % of their total protein intake from 
natural food protein, compared to 27% in group B.  This corresponded to a median 
phenylalainin intake of 746 mg/d in Group A and 808 mg/d in group B, Table 8. 
The main sources of natural protein in the diet were potato, fruits and vegetables. In 
addition small amounts of cheese and meat and fish products were used in 
maincourse dishes and as spreads on low protein bread. 
There was no significant association between serum phe levels and intake of natural 
protein or phenylalanine for the group as a whole. The total intake of phenylalanine 
from natural food was significantly higher among men than women (p=0.02), but the 
difference disappeared when looking at the phenylalanine intake in mg/kg 
bodyweight. 
Protein substitute 
Protein substitutes were the main source of protein for all subjects, Table 8. All 
substitutes were devoid of phenylalanine; 17 of 19 subjects used substitutes in the 
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form of powder containing a balanced mixture of essential and non-essential amino 
acids, fortified with minerals and vitamins. The daily dose was approximately 140 
g/d of the traditional powder, and about 100 g/d of more modern types. Two subjects 
used substitutes in the form of tablets.  The dose was 105 tablets per day of the 
product containing both amino acids and vitamins and minerals, the other containing 
only essential amino acids. The product with only essential LNAA was taken as 30 
tablets per day.  
Information sheets on protein substitutes used in the study can be found in Appendix 
13. 
 
 
 
 
 
 
 
 
 
 
Table 8: Intake of protein and phenylalanine, from substitutes and food 
  Group A Group B Total 
 N 7 12 19 
 
P 
Mean (SD) 50 (19) 58 (8) 55.2 (13.1)  
Median (Q1-Q3) 59 (43 – 60) 57 (13.8 – 31.2) 59 (51 – 71) 0.38 
Protein from 
substitute, 
g/d Min-max 13 – 71 47 – 75 13 – 75  
Mean (SD) 17 (4) 22 (8) 20.1 (7)  
Median (Q1-Q3) 18 (14 - 20) 21 (14 - 31) 19 (14 - 22) 0.26 
Natural 
protein from 
food, g/d Min-max 11 – 21 13 – 33 11 – 33  
Mean (SD) 681 (176) 856 (340) 791.4(297.4)  
Median (Q1-Q3) 746 (561 - 824) 808 (495 - 1191) 746 (499 – 952) 0.43 Phe intake, mg/d 
Min-max 370 – 841 462 – 1370 370 – 1370  
Mean (SD) 0.95 (0.33) 1.06 (0.2) 1.02 (0.25)  
Median (Q1-Q3) 1.03 (0.80-1.22) 1.0 (0.89 – 1.31) 1.02 (0.85 -1.22) 0.54 
Protein,  
g/kg 
Min-max 0.32 – 1.26 0.84 – 1.36 0.31 – 1.36  
Mean (SD) 9.3 (2.6) 11.4 (5.0) 10.6 (4.3)  
Median (Q1-Q3) 8.8 (7.1 – 11.5) 10.4 (6.8 – 14.3) 10.2 (7.1 – 13.0) 0.54 Phe,  mg/kg 
Min-max 6.2 – 13.1 5.6 – 21.3 5.6 – 21.3  
The Mann-Whitney U-test is used for differences between group A and B  
P = p-values for difference between group medians 
Q1 = first quartile or 25th percentile, Q3 = third quartile or 75th percentile 
 
“Without the diet, nobody wants to be with me.” (Subject) 
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5.5.3 Fat intake 
The median intake of fat constituted 26% of the energy, Table 6. There was no 
significant difference between the groups. More than half of the subjects had a fat 
intake according to the recommendations of 25 – 35 E%, no one had a fat intake over 
35 E% (44). A total of eight had a fat intake below 25 E% (17 – 24 E%). All 
participants had an intake of saturated fatty acids (SFA) below the recommended 
maximum of 10 E% (44). 
The Norwegian food tables do not list the individual poly-unsaturated fatty acids 
(55), thus the proportion of omega-3 fatty acids of the total PUFA was not calculated.  
However, all subjects but one had an intake over the estimated minimum 
requirements of 3 E% of polyunsaturated fatty acids (PUFA), Table 6. Only three 
(16%) subjects had an intake of polyunsaturated fat (PUFA) below the Norwegian 
mean intake of 5.4% of energy (E%) (63). Seventeen (89%) subjects met the Nordic 
recommendations of at least 5% of the energy from PUFA (44). Supplements of 
omega-3 fatty acids were taken by 14 subjects, either in the form of cod liver oil 
(n=10), or fish oil concentrates (n=4).  
 
5.5.4 Carbohydrate intake  
The mean carbohydrate intake was 59 E% for the total sample, ranging from 53 E% 
to 70E%, Table 6. 
Most carbohydrates in the diet came from refined sugar and purified starch products 
such as protein-reduced bread, baking mixtures and pasta. Apart from this, 
carbohydrate sources were natural foods like potato, fruit and vegetables. The most 
commonly used protein substitutes also contained a substantial amount of 
starch/polysaccharides, added to enhance texture and taste. Fibre was usually low, as 
low protein bread and cereal products contain little or no fibre.  
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 Added sugar 
The median intake of added sugar constituted 15% of the energy for the total sample, 
with large interpersonal variation, Table 6. Only five subjects managed to have a 
sugar intake under the recommended maximum of 10 E% (44). Subjects with a low 
sugar intake tended to have s-phe under the median for the total sample, Table 9.  
 
 
 
 
Table 9: Association between intake of added sugar and high or low mean 
serum phenylalanine 
 Mean serum phe one year prior to study 
Sugar intake =472 µmol/L < 472 µmol/L Total 
> 11 E% 8 6 14 
= 10E% 1 4 5 
Total 9 10 19 
  
Dietary fibre 
Fibre sources in the diet were fruit, vegetables and potato; some subjects obtained 
additional fibre from purified fibre products added to low protein bread. The median 
intake was 1.7 g fibre/MJ, much lower than the recommended 3 g/MJ (44). Only two 
persons, both with an intake of more than 1000 g of fruit and vegetables a day, 
managed to reach the recommendations of 25 – 35 g/d or about 3 g/MJ dietary fibre 
(44). Subjects with la ow fibre intake tended to have a higher sugar intake, Figure 5. 
Rank correlation between dietary fibre in g/MJ and energy % from added sugar gave 
a Spearman’s rho correlation of -0.75 (p<0.001). 
5.5.5 Intake of fruit and vegetables 
In the PKU diet, patients are advised to eat most of their natural protein as fruit and 
vegetables, see page 5 (16;17).  
The median intake of fruit and vegetables was 369 g per day (339 g in group A, and 
435 g in group B), Table 5. This amount is about the same as the mean Norwegian 
intake found in Norkost (mean 357 g/d) (63). The variation between subjects was 
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large, without any significant differences between the two groups or between males 
and females. There was a positive Spearman’s rho correlation of 0.49 (p<0.03) 
between intake of fruit and vegetables and dietary fibre in the diet.  
In addition to the intake of fruit and vegetables, the subjects had a median potato 
intake of 87 g/d. Mean potato intake in the Norwegian population is 135 g/d (63). 
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Figure 5: Association between intake of added
sugar and fibre in the diet  
 
 
 
 
 
 
 
 
5.5.6 Non-energy nutrients in the diet 
When the prescribed amount of substitute was taken, the intake of micronutrients was 
above the recommended daily intakes for essential non-energy nutrients (44). In 
addition to fortification of protein substitutes, low protein bread and baking mixes 
were often fortified with vitamin B and iron. Total intake of nutrients is listed in 
Appendix Table3. The intake of vitamins and minerals was higher for most subjects 
than the average Norwegian intake (63). 
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 Table 10: Intake of micronutrients according to recommended daily intake 
Total diet Protein substitute   
Micronutrient Median 
intake 
% of 
recommended 
intake 
Median 
intake 
% of 
recommended 
intake 
Upper 
level (UL) 
Number of 
subjects 
over UL 
Calcium 1196 mg 150% 972 mg 122% 2500 mg 0 
Magnesium 549 mg 157% 399 mg 114% - - 
Iron 40 mg  444% 31.7 mg 352% 25 mg 18 
Zinc 22 mg 244% 19 mg 211% 25 mg 3 
Selenium 84 µg  168% 73 µg 146% 300 µg 0 
Vitamin A a 2002 µg  222% 1001 µg 111% 1500 µg 4 
Vitamin D 18.4 µg 245% 11.3 µg 151% 50 µg 0 
Vitamin E 22 mg 220% 7.8 mg 78% 300 mg 0 
Vitamin C 222 mg 296% 122 mg 163% 1000 mg 0 
Thiamin 2.9 mg 207% 1.96 mg 140% - - 
Riboflavin 2.9 mg 171% 1.96 mg 115% - - 
Niacin b 54 mg 284% 39.7 mg 209% 910 mg 0 
Vitamin B6 4.0 mg 250% 2.9 mg 181% 25 mg 0 
Folate c 866 µg 289% 678 µg 226% 1000 µg 3 
Vitamin B12 d - - 5.4 µg 338% - - 
a Vitamin A: Upper level refers to retinol for postmenopausal women,  
  due to risk of osteoporosis – only women >50 years of age counted 
b Niacin: Upper level refers amount in fortification 
c Folate: Upper level refers amount in fortification  
d Vitamin B12 was only calculated for protein substitutes
 
The two subjects who used tablet substitutes had the lowest intakes for all 
micronutrients. The tablet substitutes gave intakes of vitamins and minerals below the 
Norwegian recommendations for magnesium, vitamin C, vitamin D, folate and B12. 
One contained less than the recommended amount of calcium, and the other one had 
less vitamin A. But when intake from food and substitutes were calculated together 
the recommendations were met for all nutrients, possibly excluding B12, as the diet 
had few sources of this vitamin (44). 
By listing both the intake from substitutes and the total diet, the amount of 
fortification becomes evident, Table 10. Intakes from substitute alone gave median 
intakes over recommendations for all micronutrients apart from vitamin E. For 
vitamins A, C and E food intake constituted about half the total intake. For other 
vitamins and minerals, the proportion from substitutes varied from ca 60% to almost 
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90% of the total intake. For iron the upper level was exceeded from the intake of 
protein substitute alone. Also the intakes of zinc and folic acid were high, and three 
individuals had intakes above the estimated upper level for zinc, and thre for folate 
(44). The four female subjects over 50 years of age all had intakes of vitamin A 
above the estimated upper level given for postmenopausal women. Seven women 
younger than 50 years of age also had intakes over 1500 µg/d.  
The two persons using tablet substitutes ingested 0.9 and 1.0 µg/d vitamin B12 from 
substitutes, one had B12 deficiency. For the remaining 17 subjects B12  intake from 
substitutes ranged from 4.3 to 11.8 µg/d.  
Daily doses of powdered protein substitute resulted in intakes of 500 – 900 µg/d of 
folate. Food intake gave about 200 µg/d, ranging from 110 – 320 µg/d.  All subjects 
had folate intakes over the Norwegian mean of 240 µg/d and the Nordic 
recommendations of 300 µg/d (44;63).  
 
 Figure 6: Distribution of iron intake 
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iron intake of 40 mg/d, ranging from 24.6 to 57 mg/d, Figure 6. The estimated upper 
level for intake is 25 mg/d and 18 of 19 subjects had intake of iron above this level 
(44).  
 
Figure 7: Iron intake in association to blood iron parameters 
 
 
The protein substitute alone gave a median iron intake of 31.7 mg/d (range 12.3 – 40 
mg/d). The fortification of low protein bread and baking mixes gave a median of 6.6 
mg/d (range 1.9 – 15.4 mg/d). Iron intake from other natural food sources had a 
median of 3.7 mg/d (range 1.6 – 7.2 mg/d), with only 0.6 mg/d (range 0.0 – 1.8 mg/d) 
from products containing meat or fish. The high intake was not reflected in high 
levels of iron status in blood, Figure 7. The blood tests did not reveal signs of iron 
overload despite the high iron intake.  
 
“Sometimes it’s crap! Having PKU and fixing the diet.” (Subject) 
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6. Discussion 
There is ample documentation that late dietary treatment is effective in reducing 
behavioural and neurological signs in PKU. At least half of the patients who start 
dietary treatment as adults display benefit (9;27). It is also stated that these effects 
persist providing serum phe levels are low (10;22;25).  
The dietary composition and nutritional results will be discussed after the phe levels 
in serum. Thereafter will themes related to adherence and living on a PKU diet be 
discussed. 
6.1 Phenylalanine in serum 
Blood phenylalanine for all subjects in this study was efficiently lowered by the diet. 
However, all subjects in group A had mean phe levels above Norwegian treatment 
recommendations. Subjects in group B had levels closer to the standards, but only 
three managed to keep a mean level below 400 µmol/L. As recommendations on 
serum phe levels are lacking for adults with late commencement of treatment, finding 
the optimal individual level for adults will always be a compromise between 
treatment effects and a practical and manageable everyday diet. This is also reflected 
through other studies on late treatment where some aim at phe levels below 600 
µmol/L, others are satisfied if serum phe falls below 1000 µmol/L (9;24;27).   
Adults will have fairly stable blood phe levels when the diet supplies sufficient 
energy, sufficient protein substitute and natural protein to meet individual 
requirements of phenylalanine. In absence of illness or changes in bodyweight, 
fluctuations in the blood phenylalanine are caused by dietary variations. In the 
present study this was demonstrated by the correlation between the serum phe taken 
at the time of food recording and mean phe prior to the study, see Table 3 and Figure 
1.  
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From the data it may be concluded that the Norwegian upper limit for serum 
phenylalanine is impracticably low and not manageable for adult patients with brain 
damage. It seems easier to keep low levels for patients living in group homes with 
full support, than for adults living independently. However, the two groups had few 
participants and the difference in phenylalanine levels between groups was not 
significant.  
6.2 Composition of the diet 
6.2.1 Do the weighed food registrations give valid results? 
The assumption that the registrations reflected habitual intake was supported by the 
subjects’ dietary routines, with fixed amounts of  natural protein and protein 
substitute from day to day (5). Usually subjects in group B followed detailed lists or 
menus, stating food types and amounts of phenylalanine to be taken at each meal. 
Also the subjects in group A had lists for help in determining amounts of protein rich 
foods, but their routines and meals were not as closely planned as in group B. The 
blood phenylalanine levels during the study were closely correlated to individual phe 
levels in the past, indicating that the intake of natural protein was fairly stable. 
Further support was found in the food registrations. The energy intake recorded gave 
an estimated physical activity level (PAL) above Goldberg’s cut-off limit for healthy 
sedentary adults (61). PAL was however, lower for subjects in group A than in group 
B. This can be due to gender differences, as group A consisted mainly of women who 
tend to have lower PAL than men. Another reason may be that people tend to eat less 
when recording their own intake (61;64).   
Underreporting is more common when people report their own intake, than if 
reporting is done by “neutral observers” as reported by Westerterp and Goris (65). 
However, caregivers, especially parents of disabled children, tend to overreport 
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intake (65). This tendency must be considered when studying profoundly retarded 
adults as subjects in group B. But as all subjects in this study had BMI>20, and no-
one had eating problems resulting in insufficient energy intake over time, the 
tendency to overreport seems less probable.  
A tendency to underreport, as seen among obese or overweight people seems less 
probable in this study as most subjects did not reflect on their own body appearance 
(61;64;65). Neither did subjects with high BMI have lower PAL values than subjects 
with BMI in the normal range. In addition intake of low protein snacks and sweets 
were reported, often in ample amounts, both by subjects with normal and high BMI. 
It may be concluded that the food registrations are reliable and give valid results. 
There were no significant differences in intake between the two groups, but each 
group was small in number and varied in distribution of sex, age and activity levels. 
 
6.2.2 Bodyweight and energy intake 
The prevalence of overweight among the participants (Table 7) was above the 
Norwegian mean  BMI=26.5 for men and 25.2 for women (66). Several studies from 
Western countries have shown a higher prevalence of overweight and obesity among 
people with mental retardation than among the general population (67-69). This 
corresponds to the present study where 75 % had BMI>25 and the subjects in group 
A had median BMI of 28.  
There was no significant difference in distribution of BMI between the two groups. 
This differs from the Norwegian study by Hove, who reported a higher prevalence of 
overweight and obesity among persons with mild mental retardation and living 
independently, than in the normal population or mentally retarded residents in group 
homes (69).  
Hove also reported that underweight was more common than overweight among 
severely retarded people; probably due to a high prevalence of feeding problems, 
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food refusal and lack of independent choice (69). This tendency was not observed in 
the present study. Some case studies of late treatment for PKU describe normalisation 
of bodyweight and reduction of eating problems after institution of dietary treatment 
(24;25). This is in accordance with information given in the interviews and from 
hospital charts; five subjects in group B suffered from eating refusal and low body 
weight prior to treatment, but developed better appetite and gained weight whilst on 
diet. Apart from case reports, information on bodyweight in adults with PKU is 
lacking.  
The relative high BMI in this study might be due to substantial amount of “hidden” 
energy from the protein substitutes. Both subjects and caregivers tended to define the 
substitute as a medicine instead of food, and therefore the energy contents were often 
not appreciated. Accordingly, the portions of food allowed without restriction might 
increase, and this could result in an excess energy intake. In addition, the intake of 
added sugar was high, partly because drinks and sweets were predominantly chosen 
in variants containing sugar. Artificial sweeteners were usually avoided because 
aspartame contains phenylalanine.  
6.2.3 Protein intake 
No controlled studies have concluded that PKU patients have requirements for 
protein that vary from those of the normal population (70-72). In the present study all 
subjects but one had protein intake in accordance to  recommendations (44). For 
babies and young children however some treatment centres recommend higher 
intakes (5;70;71). The sum of protein substitute and natural protein should, according 
to a Cochrane review from 2005, provide recommended amounts of total protein, 
adjusted for age (70). All subjects seemed to receive an appropriate amount and 
quality of protein over time when the data were considered together. One subject had 
an intake of protein of only 0.37 g/kg. This was not associated with subnormal blood 
analyses, so this subject probably used to eat more natural food with protein. 
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The intake of phenylalanine varied according to individual tolerance. For subjects 
with similar serum phe levels the intake of phe from food in mg/kg could vary as as 
much as 100%. This was due to individual differences in the impairment of the PAH-
activity, in food absorption, age, weight and variation in the metabolic turnover of 
phenylalanine (1;11).  If an individual subject wished to obtain lower serum phe 
levels, he or she would have to ingest less dietary phenylalanine than before. This 
would mean greater restrictions in natural protein, and a diet more problematic to 
follow.  
All subjects in the present study took their protein substitute every day, even though 
the taste and smell of the powder substitutes are extremely unpleasant to most people. 
Information from the interviews showed that single doses of substitute could be 
forgotten, especially in group A. In group A some subjects also had changed to a 
different substitute because of the taste and smell. Problems in taking the substitute 
were surprisingly few among subjects in group B. According to information given in 
the interviews most subjects in group B accepted and even liked, the protein 
substitute. Even so, some subjects needed persuasion or extra praise to drink the 
substitute. One subject took a very long time, and took less than prescribed several 
times a week. The fact that retarded patients easily accept the substitute is also 
reported by Fitzgerald et al (24); other reports mention that the substitutes were a 
smaller problem than expected by  caregivers and dietitians (9;10;25;27).  
The unpleasant flavour is, however, a reason for non-adherence to the diet in well 
functioning and early treated adolescents and adults according to literature (73;74), 
this complies with the experiences from group A.  
In this study recommendations for protein or nitrogen intake were met when the 
prescribed amounts of natural protein and protein substitute were taken (44). 
Differences in amounts or types of protein varied according to phe tolerance and 
body weight and not to the degree of mental retardation. One person in group A had a 
low intake of protein during the registration period. The amount of natural protein 
eaten was similar from day to day, indicating that this subject was not able to 
understand or follow the dietary advice provided. This shows that patients with 
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milder disabilities might need help and supervision by people who are familiar with 
the dietary principles.  
6.2.4 Fat intake 
Without conscious use, the energy from fat in the PKU diet will not reach the 
recommended 25-35 % of energy intake (44). In this study almost half of the subjects 
had a fat intake below the recommendations and a risk of deficiency in essential fatty 
acids was present.  
Fatty food products in a normal Norwegian diet usually contain protein. These 
products were used in small amounts, and portions of food like cheese, meat and 
chocolate varied from 2 to 20 g/d. The negative correlation normally seen between 
energy from fat and sugar is therefore less apparent in a PKU diet, and did not reach 
significance in the present study. The main sources of fat were vegetable margarines, 
vegetable oils and mayonnaise dressings, all rich in unsaturated fatty acids. Sources 
for saturated fat (SFA) were cream and a special low protein milk. Some subjects, 
mainly in group A, also received saturated fat from low protein biscuits, chips and 
butter.  
Low concentrations of the long chain polyunsaturated fatty acids (LCPUFA) 
arachidonic acid (AA) and docosahexaenoic acid (DHA) have been reported in blood 
from children and adults with PKU (38;39;41;75). Some reports find AA and DHA 
more compromised than their precursors, linoleic and α-linolenic acid. According to 
Infante and Huszagh this may be due to inhibitory effects on endogenous synthesis of 
AA and DHA by elevated phenylalanine or its metabolites (42). Supplemention with 
essential fat, either as linoleic and α-linolenic acid or as LCPUFA, has shown to 
improve fatty acid balance in children’s plasma and erythrocytes (38;39;75). Moseley 
et al. found low levels of LCPUFA also in adults, but these were less severe than 
those formerly reported in children (41). They also reported higher DHA values when 
serum phe was below 600 µmol/L.  
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The fat sources registered in the present study showed that intake of linoleic acid, and 
thus probably arachidonic acid, were met in the diet when fat of vegetable origin was 
used. All subjects had been advised by the dietitian to take supplements of fish oil 
concentrate or cod liver oil to ensure a minimum intake of DHA. As fat had to be 
chosen specially to obtain sufficient DHA , the intake may have been suboptimal for 
some individuals. Fish oil supplements were used in very small doses by some and 
not all by seven.  
The present data support the hypothesis that patients with PKU involving brain 
damage can obtain sufficient amounts of fat and LCPUFA through the diet. However, 
advising patients to supplement the diet with fish oil seems reasonable in order to 
secure intake of DHA. The majority of subjects in this study, 16 out of 21 (five in 
group A and 11 in group B), had a mean serum phe below 600 µmol/L, thus the risk 
of inhibitory effects from phenylalanine upon DHA and AA synthesis seemed low 
(41). 
It seems important to give repeated advice on the preferred types of fats in the diet, in 
order to secure intake of essential fat, and reduce the risk of replacing unsaturated fat 
sources with saturated fat.   
The degree of mental retardation or need of support did not seem to interfere with the 
total intake of fat. But subjects in group B ingested more essential fat even though the 
difference between groups did not reach significance.  
6.2.5 Carbohydrate intake 
A high energy percent of sugar will usually have adverse effects on the intake of 
micronutrients from food. In the PKU-diet however, sugar intake influences the total 
nutrient intake only to a small extent, as the majority of micronutrients are supplied in 
the protein substitute. Most subjects in group A reported to use sweets and protein-
reduced biscuits or cakes for snacks, when eating away from home and at social 
occasions. Sweets and soft drinks are easily available and many types can be enjoyed 
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in unrestricted amounts. This reduced the need for planning, cooking and bringing 
along special food, but it also reduced the overall quality of the diet. 
According to Nordic recommendations less than 10% of the total energy should be 
refined or added sugar (44). This is far less than most subjects in group A used.  Also 
in group B subjects used more added sugar than recommended, mostly from soft 
drinks or conserves; often taken in spoonfuls with medicine. Sweets were regularly 
used as treats, for instant after taking the protein substitute.  
Subjects with a low intake of added sugar tended to have s-phe under the median for 
the total sample, Table 9. The food registrations showed that subjects with low a E% 
from sugar used smaller portions of soft drinks, snacks and sweet spreads on bread. 
However, the number of food products, total amount of fruit and vegetables or fat did 
not vary according to sugar consumption. Subjects with a low intake of added sugar 
also adhered better to dietary prescriptions when evaluated by serum phe levels. 
Perhaps they also were more meticulous with food containing natural protein. 
The intake of dietary fibre was compromised when products abundant in sugar 
replaced other kinds of natural low protein food, Figure 5.  The seven subjects with 
more than 15 E% from added sugar had very low intakes of fibre (ca 1 g/MJ).  
The low fibre intake may also have increased the risk of constipation, a problem 
reported from several subjects in the interviews. To increase fibre intake, some 
subjects, mainly in group B, used small amounts of purified fibre products in the low 
protein bread, and some used oats or whole grain wheat in porridge. A positive 
change in the diet would be to add fibre to low protein bread and baking mixes. This 
should preferably be done at production level, as all procedures which complicate 
food preparation are negative in such a demanding diet, specially for subjects in 
group A who receive little or no practical support.  
Data showed that it was difficult for adults with brain damage to manage a diet in 
compliance with recommendations regarding amounts of added sugar and dietary 
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fibre. However, a couple of the subjects showed that it was possible. The difficulties 
seemed similar in both groups, and not related to the degree of mental retardation. 
6.2.6 Micronutrients 
Fortification of protein substitutes resulted in excessive intakes of micronutrients for 
all subjects taking the powder substitutes, Table 10. The high intake resulted in 
abnormally high concentrations of folate and vitamin B12 in the blood. However, this 
effect was not seen in other blood parameters such as iron, zinc or magnesium. Due 
to the high intakes of protein substitute in order to maintain low serum phenylalanine 
levels patients with low tolerance for dietary phenylalanine will have the highest 
intake of micronutrients.  
These data demonstrate the problem of optimal fortification. Clearly, semi-synthetic 
diets for metabolic diseases like PKU need fortification to secure a sufficient intake. 
However, the necessity for large doses should be documented. There are available 
studies describing the balance and metabolism of several micronutrients in patients 
on a PKU diet (37;43;76-78). The majority refer to concentrations in blood without 
reporting the correspondent intake and the studies are usually related to children. 
Study controls are often siblings or healthy children, who obtain their micronutrients 
from natural food in much smaller amounts than subjects with PKU.  
Documentation is needed, both on the effects and side effects of excessive intakes. 
Documentation is important in dietary follow-up both for clinical reasons and for 
better adherence. Smaller doses of micronutrients could perhaps enhance the taste of 
substitutes and reduce the osmolality for these highly concentrated mixtures. In the 
present study some subjects reported abdominal discomfort after taking the 
substitutes, possibly due to the high concentration or to the large volumes.  
From a nutritional point of view the bioavailability of the compounds used in 
fortification should be the best possible. They should also interfere minimally with 
solubility or taste of the finally prepared substitute.  
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Fortification of the protein substitute is the common way to give micronutrients in 
PKU as it reduces the necessity for additional supplements. This makes the diet less 
complicated and increases adherence (74). The powder substitutes used in this study 
were recommended both for children over eight years of age and for adults. However, 
it  is impossible to obtain the correct balance of protein and micronutrients from the 
same product for a child of 30 kg and a man of 90 kg (44).  
Folate and B12 
Serum folate is strongly correlated to the recent intake of folic acid or folate. Folate 
levels in erythrocytes reflect tissue stores. The high levels indicated a high folate 
intake over a longer time, showing that the subjects did take their protein substitute, 
see Figure 4. 
Robinson et al (79) believed that the high erythrocyte folate levels in PKU were a 
result of a high vegetable intake, but without reporting the dietary intake. Also 
Colomé et al (80) reported high serum folate in treated PKU subjects, without 
reporting folate intake. In the present study the majority of folate was folic acid from 
fortification, as levels from food intake were below  the recommended amounts, 
Table 10 (44). Even if vegetable intake had been doubled, fortification would 
constitute most of the total folate intake.  
There are indications of interaction between folate and biopterine in PKU. 
Tetrahydrobiopterine (BH4) is a coenzyme for PAH in the conversion of 
phenylalanine to tyrosine (1). Lucock et al studied folate metabolism in PKU (43),  
and reported higher concentrations of certain stable folate metabolites in erythrocytes 
in PKU patients than in controls. This was found in subjects both on and off diet. The 
significance of this altered folate metabolism remains unknown. Smith et al discussed 
whether the blood levels unmetabolised folic acid seen after fortification may be 
harmful or possibly interfere with the folate metabolism (81). They were also 
concerned about the unknown consequences of high intracellular concentrations and 
concluded that fortification with folic acid needs further investigation. 
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None of the reports give evidence for higher requirements for folate in PKU, and it 
remains unclear if the high erythrocyte folate is beneficial for PKU patients. Whether 
the high folate in blood tests is influenced by an altered metabolism in addition to an 
increased intake cannot be concluded from this descriptive study. 
The high intakes of vitamin B12   were also reflected in the blood samples, Table 10. 
Several reports show that PKU adults not adhering to the diet have a risk of 
developing B12 deficiency because the patients stop taking the substitute without 
managing to eat a “normal” healthy diet (77;79;82). In this study the deficiency 
seemed rather due to insufficient fortification of the protein substitute used. In 
contrast to the tablet substitutes, the powders supplied abundant B12 , resulting in 
blood levels above the upper limits for normal concentration. To reduce risk of 
masking a vitamin B12   deficiency it is important that the fortification with folic acid 
is balanced with high amounts of vitamin B12   (81) 
Iron 
There was no correlation between the high iron intake and iron status. Similar 
absence of correlation between intake and iron status is reported in children by  
Acosta et al and by Arnold et al (37;83). The high amounts of dietary iron did not 
seem to have beneficial effects on the subjects’ iron status. 
The iron sources in the diet had poor bioavailability as the amounts of haeme iron and 
the enhancing factors for iron absorption in meat, fish and poultry were negligible. 
The intake of iron from natural food varied from 1 to 6 mg/d and was below the 
estimated lower level of intake, and showed that supplementation was needed (44). 
Dietary iron is generally poorly absorbed and the iron salts used for fortification have 
an even lower bioavailability (44). The substitutes used in this study were fortified 
with iron sulphate, iron gluconate and iron fumarate. In addition the most common 
baking mix was fortified with elemental iron (ferrum reductum). 
Some essential micronutrients in the protein substitutes are known inhibitors of iron 
absorption. For example will doses of more than 165 mg calcium in a single meal 
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cause a 50% reduction in iron uptake (44). In the PKU diet this inhibition will take 
place at all meals containing protein substitutes and may result in high amounts of 
intestinal iron. Local intestinal toxicity is reported as a side effect of iron intakes 
beyond 50-60 mg/d (44). Only two subjects had intakes this high, but six more had 
intakes above 40 mg/d. It is, however, reasonable to suggest that the high iron intake 
in combination with the low fibre intake aggravates intestinal problems such as 
constipation.  
The substitutes also contain enhancers for iron absorption, such as vitamin C (44). 
The enhancers evidently did not counteract the inhibitors sufficiently enough to 
improve iron absorption. It seems relevant to ask if fortification with haeme iron in 
lower concentration can better iron status, and reduce the excessive fortification.  
According to the nutrient intake and the blood analyses available substitutes did not 
seem to be optimal for treatment of adult patients. Intakes of most minerals and 
vitamins were above recommendations when protein substitute was taken in the 
amounts required. The excessive amounts resulted in intakes close to or above 
estimated upper levels for some nutrients.  
Possible harmful effects from excessive fortification need further investigation. 
6.2.7 Fruit and vegetables 
Fruits and vegetables can to a great extent be used without restrictions in the PKU 
diet as reported by MacDonald et al (32). Despite this, intake in the present study was 
only a little higher than the mean Norwegian intake reported by Johansson and 
Solvoll (63). The amounts and types used varied greatly between individuals. 
Subjects with a fruit and vegetable intake over the median had a larger diversity of 
natural food products in their diet than subjects who ate little fruit and vegetables. 
The total intake of natural protein or phenylalanine from food was not influenced by 
the amounts of fruit and vegetables in the diet.  
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Only two subjects in Group A had an intake of fruit and vegetables above the median 
for the total group. One of them received extensive support from parents, and the 
other suffered from diabetes mellitus and put great effort into organising meals 
according to the lists from the dietitian. Three subjects in group A had very low 
intakes; two of them received no support in dietary matters. Support in cooking and 
everyday organisation of the diet seemed important in helping subjects in group A to 
include a wider use of fruit and vegetables in their diet. 
Intake of fruit and vegetables in Norway has traditionally been low (84), and the 
subjects in group A had learned cooking and household skills in a period when fruit 
and vegetables were used in smaller amounts. Advice from the dietitian had not 
changed their perception of fruit and vegetables as supplementary food instead of a 
main ingredient in their diet. The fact that they had learning disabilities and problems 
in acquiring new knowledge and skills, may also contribute to a greater reluctance to 
change habits and experiment with food products and tastes.  
In group B the interviews revealed that intake of fruit and vegetables was dependent 
on knowledge, cooking skills and opinions on healthy food amongst the staff. For 
eight subjects, lists and scales were used for all foods containing protein, including 
fruit and vegetables. The others used fruit and vegetables in free amounts. This 
difference in organisation did not result in any differences in subjects’ intake.  
Caregivers were more prone to serve fruit and vegetables if these products were 
explicitly mentioned in menus or diet plans. If the plans only listed the amount of 
phenylalanine to be used, often small amounts of protein rich food was used instead. 
In order to reach the national goals of “five a day”, dietitians must recommend fruit 
and vegetables as an option at each meal. In this way the total volume of normal food 
products in the diet will increase. Trained staff members, with adequate knowledge of 
the diet, reported that they were more liberal with fruit and vegetables than staff 
members with less knowledge and routine. Some reported they had started to serve 
fruit and berries to all residents, replacing some of the cakes and biscuits for 
afternoon coffee.  
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The data show that the recommendation “five a day” is compliable with a PKU diet, 
but it requires special consideration and a new perception of which food products 
should constitute the basic diet. It is known that an increased use of fruit and 
vegetables is easier to obtain when subjects have health risks known to be influenced 
by diet (85;86). However, the subjects in the present study had already carried out 
changes according to health needs. It appeared problematic for them to alter eating 
habits even more, despite the fact that more fruit and vegetables would result in a 
greater variation in the diet. Increased use of fruit and vegetables would also enhance 
the intake of naturally occurring components as dietary fibre and antioxidants. 
 
“People want to be kind, and she appreciates fruit. If you give her other 
things, may be she’ll be happy at the moment, but the next day she’ll 
feel poorly.” (Caregiver) 
 
6.3 Living on a PKU diet 
Information from the interviews showed that having PKU and adhering to the diet 
was experienced as problematic by all subjects in group A. However,  they still 
wished to follow the diet and managed to do so most of the time. A discussion on 
quality of life among people with brain damage due to PKU is beyond the scope of 
this study, but aspects related to management and adherence will be discussed. This 
section is based mainly on qualitative methods and data from the interviews (52;53). 
Adherence is defined as the extent to which a person’s behaviour corresponds with 
and agrees with recommendations from health care providers (87). Hopefully, the 
discussion can point out some factors important for better adherence among patients 
with brain damage due to PKU.  
Studies show that adhering to dietary treatment is challenging even when necessary 
for health and wellbeing. Sherman et al report that adherence to a dietary regime is 
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influenced by both individual and social barriers and is more challenging than 
adhering to pharmacological treatment (88). One aspect is that medical diets are not 
easily adapted to meet the social, cultural or religious properties of food. This can 
lead to a feeling of deprivation and of being socially excluded. Additional barriers are 
lack of availability and cost of special food products as pointed out by MacDonald et 
al (74).  
In group A barriers to adherence were elucidated in behaviour related to eating away 
from home or at special social occasions. Most subjects preferred to take normal food 
products; based on sugar or as small amounts of other food, in stead of bringing along 
special products or asking to be served special dishes. In this way the subjects also 
reduced the need for planning and cooking. In using the same food as others the 
feeling of deprivation or being different became less prominent. The subjects 
reported that the diet was emotionally challenging because of the small amounts of 
natural food, the taste and smell of the substitute and a feeling of being different. 
Ievers-Landis et al reported similar findings in children and adolescents (73). These 
feelings seemed to be a part of having PKU and adhering to the diet, and were 
independent of serum phe levels and how well the diet was managed.  
Perception of these problems was not always noticeable among caretakers, who did 
not drink the substitute or face temptations themselves. Caretakers’ problems were 
expressed as related to cooperation among staff, available time for planning and 
cooking, and in challenges of composing a varied diet .  Some caretakers expressed a 
need for more support and knowledge. This was not available locally because of PKU 
being so rare. Most patients are diagnosed early, after newborn screening, and 
knowledge and skills in self-management can be transmitted gradually. For adults 
with brain damage due to PKU, the need for information and knowledge from the 
central treatment centre has to be renewed when new caretakers are employed. This 
need for support must be understood and acknowledged by the national  PKU-team 
and The Centre for Rare Disorders at Rikshospitalet. 
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In contrast to the request for knowledge by the employed caregivers,  psychological 
and emotional aspects are described as more important than knowledge for 
maintaining dietary procedures by the patients with PKU and their parents (86;88-
90). Bekhof et al found that knowledge is necessary only to the extent of making the 
diet feasible and practical (91).  Being convinced that treatment results in a better life 
and less symptoms is more important for adherence. Waisbren et al used the method 
“Theory of planned behaviour” to describe necessary factors for individual adherence 
(92;93). The factors are 1) “subjective norms”; or feedback and support from 
important others, 2) “attitudes”; or personal beliefs and experiences that diet is 
causing a decrease in symptoms, 3) “manageability”; or a perception of the diet as 
manageable.  
The “important others” include relatives, friends and supportive professionals. In this 
study the PKU-team at Rikshospitalet acted as “important others”, both to subjects in 
group A and to the group home staff who administered the diet in group B. In 
accordance with Sherman, sensitive and personally adapted feedback was reported as 
important incentives for adherence (88). To build stronger “subjective norms”, people 
need to have support available on a day to day basis and closer than the national 
PKU-team at Rikshospitalet can render. The need for practical and emotional support 
was clearly voiced by subjects in group A. Some need daily help and supervision, for 
others support on a weekly basis might be sufficient.  
Reports from both groups stated that the diet was laborious and impractical, but the 
overall impression was that it was effective and important for subjects’ wellbeing. 
Thus the “attitudes” seemed firmly anchored (92). However, in some group homes 
primary caregivers reported disagreement on attitudes. Some members of the staff, 
often with little knowledge of PKU and the subject, were opposed to the treatment 
and felt that the restriction of the resident’s personal choice was an ethical problem 
(24). This problem was most apparent in newly employed staff members or if 
immediate behavioural effects of phenylalanine elevations were difficult to observe. 
In these homes documentation on treatment effects or fluctuations in serum phe levels 
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were unavailable to staff members. The relation between diet, serum phe and 
behaviour could be difficult to discover or document as caregivers worked at 
different times during the day. For some subjects negative behaviour and depressive 
moods were clearly related to high levels of serum phe, but others could have similar 
behaviour problems as reactions to stress or illness, independent of serum phe. 
Available documentation on diet and serum phenylalanine history seemed to be 
helpful for sustained adherence in group homes; providing caregivers had learned to 
understand them. In order to learn whether behaviour problems were related to 
dietary changes or varying serum phe, caregivers needed feed back the metabolic 
dietitians. General information on PKU and competence in dietary skills for all staff 
members working with the subject with PKU seemed important for adherence in 
group B. 
In group A the “manageability” was inadequate for some subjects, and this had 
resulted in periods of non-adherence in the past. Subjects receiving practical support 
from parents or community services managed to maintain lower mean serum phe and 
had better everyday routines. This is an important argument for organising local help 
and supervision. The parents acknowledged these problems, but reported difficulties 
regarding the local welfare authorities and their understanding the need for support.  
Manageability in group homes seemed to depend on good organisation and routines 
as well as mutual agreement on treatment. All homes had one or two staff members 
responsible for the diet, and in some homes the whole staff had a basic knowledge of 
PKU and the diet. The latter seemed to improve staff cooperation, and was supportive 
for the caregivers with main responsibility. Agreement on treatment and the 
significance of maintaining a strict diet seemed as important as written routines and 
procedures. In this way the factors of attitude and manageability seemed intertwined.  
A main prerequisite for dietary adherence and management for adults with brain 
damage who are treated for PKU and living independently is a need for support from 
their local community. The amount of support necessary will vary according to 
individual needs, but will be needed for organising, ordering special products and 
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cooking. Individuals who render assistance or support require knowledge of PKU and 
should have some basic skills in preparing low protein food.  
Support should be organised on a permanent basis and secure follow-up of the 
caretakers as well as the patients. Cooperation between local welfare authorities and 
the central follow-up system at Rikshospitalet is required. The Centre for Rare 
Disorders supplies support and information to persons with PKU, their relatives and 
professionals working with the diagnosis in local communities. This study illustrates 
that there is still much to do and that information needs to be rendered on a more 
systematic basis. 
 
“I wish she had more support. In order for her to manage somebody 
has to know, she won’t have me for ever.” (Parent) 
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7. Conclusions 
The objective of this study was to describe the composition and management of a 
protein restricted diet for PKU. Questions were raised in respect to whether 
nutritional recommendations were met and to prerequisites for adherence.  Two 
hypotheses were formulated and tested in order to answer these questions, see page 
17???. 
The subjects formed a subgroup within the PKU population. Age, mental function 
and requirements of support varied between the 21 subjects who were divided into 
two groups according to mental functioning. The study was designed in order to 
minimise the impact on the brain damaged subjects, limiting the number of blood 
tests taken and the obtainable analyses. Despite a high participation rate, the 
participants were few and this made it difficult to demonstrate statistical significance 
between the two groups, and thus made it more difficult to generalise the results. 
However, the PKU diet leaves little room for variation regarding the amounts of 
protein and micronutrients in the diet. This conformity makes it possible to generalise 
certain results from the food registrations to other adults adhering to a PKU diet.  
The food registrations showed that adults with brain damage due to late diagnosis of 
PKU, as hypothesised, could manage a diet in accordance with the Nordic Nutrition 
Recommendations. However, this required great effort and special considerations 
regarding food choice. The intake of protein from the substitute and natural protein 
was sufficient, however, the first part of hypothesis one could not be confirmed due 
to the following reservations:  
• The intake of fat was below recommendations for many subjects, and special 
caution had to be taken to secure intake of essential fatty acids.  
• The subjects had high intakes of added sugar, the median intake was 15 E%. 
The intake of fibre was low, especially in individuals with a high sugar intake.  
• If precautions were not taken to choose more natural protein as fruit and 
vegetables, the recommendations for fibre and five portions of fruit and 
vegetables a day were not met.  
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Even when the diet fulfils the nutritional recommendations, biomarkers for nutritional 
status showed suboptimal or deviant results for individual subjects. For 
micronutrients this was due to the composition of the protein substitutes and could 
not be controlled by the subjects or caregivers.  
• This shows that the second part of the first hypothesis was not confirmed due 
to the following reservations:  
• All subjects had high intakes of micronutrients, and the majority used protein 
substitutes fortified with excessive amounts of vitamins and minerals.  
• The high intake of folic acid and vitamin B12 was reflected in high blood 
levels. 
• The iron status in blood was not elevated although intakes were above the 
estimated upper level of intake.  
• Fortification of the diet is necessary, but the amounts and types of compounds 
used to fortify the substitutes need to be evaluated and further investigated.  
• The proportion of overweight was higher in this study than in the general 
Norwegian population. This could be due to low physical activity and mental 
retardation as well as the energy content of the protein substitutes or the 
widespread use of food products rich in sugar. 
 
The third part of the hypothesis was not confirmed as the subjects did not manage to 
maintain serum phenylalanine according to Norwegian treatment recommendations.  
• The upper recommended level for serum phe (<400µmol/L) was not 
manageable for the majority of subjects. All subjects had lowered their serum 
phenylalanine substantially, but very few managed to maintain serum phe 
levels according to the recommendations. 
 
The statement in the second hypothesis was partly confirmed. Despite few significant 
differences between the two groups, however, the degree of mental retardation 
appeared to have impact on how the diet was managed:  
• The subjects with mild mental retardation, who lived independently, faced 
greater challenges in following the diet than subjects in group homes. This 
difference was related to the degree of support the subjects received. Subjects 
with practical support from parents or the community managed to maintain 
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lower serum phe levels and had better everyday routines than the subjects 
without regular support.  
• Manageability in group homes depended on mutual agreement on the 
importance of treatment and a basic knowledge of PKU among the staff to 
improve cooperation and support caregivers with main responsibility. 
• Adults with brain damage due to PKU, and their caregivers, need sufficient 
support from their local community. Help must be taylor-made to cater for 
individual needs.  
 
Better knowledge of how patients with PKU and their caregivers translate the advice 
and prescriptions into an everyday diet may improve the dietary treatment. This study 
has provided new knowledge that can prove important in regard to giving dietary 
advice and in organising follow-up of persons with PKU and brain damage 
The results show that further investigation into the nutritional impact of this semi-
synthetic diet is required. 
The results from the present study can be used to stimulate the cooperation between 
local and national treatment and support systems. 
 
“It is kind of lonely, the colleagues ask me, but I have nobody to talk to. 
I wish that persons working with PKU residents could get into contact. 
I wish there were more frequent courses and follow-up for the group 
homes.” (Caregiver) 
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Appendix table 1: Amino acids in serum 
(other blood parameters in Appendix table 2) 
 
  Group A Group B Total 
 N 7 8 15 
Comments1 
Mean (SD) 57.7 (14.4) 85.5 (42.0) 72.5 (34.3)  
Median (range) 58 (36-82) 68.5 (45-150) 60 (36-150)  Taurine, µmol/L 
Normal range   30-80  
Mean (SD) 0.3 (0.8) 0 0.2 (0.6)  
Median (range) 0 (0-2) 0 0(0-2)  
Phosfoetanol-
amine, 
µmol/L 
Normal range   0-4  
Mean (SD) 3.6 (1.0) 14.6 (4.0) 9.1 (14.6) 2 improperly 
Median (range) 4 (2-5) 3.5 (3-51) 4 (2-51) prepared, Aspartic acid, µmol/L 
Normal range   0-4   
Mean (SD) - - -  
Median (range) 4 (trace-8) 4 (trace-9) 4 (trace-9)  Hydroxyproline µmol/L2 
Normal range   0-47  
Mean (SD) 120 (26.9) 113.6 (19.6) 116.6 (22.6)  
Median (range) 115 (90-161) 118 (90-146) 115 (90-161)  Threonine,  µmol/L 
Normal range   84-196  
Mean (SD) 92 (19.1) 112.5 (37.4) 102.9 (31.1) 2 improperly 
Median (range) 86 (67-123) 96 (61-172) 95 (61-172) prepared, Serine, µmol/L 
Normal range   54-158  
Mean (SD) 46.9 (8.4) 53.8 (15.5) 50.5 (12.8)  
Median (range) 47 (33-58) 53 (33-78) 51 (33-78)  Asparagine, µmol/L 
Normal range   36-80  
Mean (SD) 33.7 (12.9) 86.9 (76.0) 62.1 (60.9)  
Median (range) 30 (16-57) 54 (21-253) 43 (16-253)  Glutamic acid, µmol/L 
Normal range   0-44  
Mean (SD) 560.4 (50.4) 497.6 (76.8) 526.9 (71.3)  
Median (range) 552 (472-627) 487.5 (381-610) 540 (381-627)  Glutamine, µmol/L 
Normal range   426-802  
Mean (SD) 142.1 (37.3) 156.5 (51.2) 149.8 (45.5)  
Median (range) 124 (110-194) 155 (94-238) 141 (94-238)  Proline, µmol/L 
Normal range   58-294  
Mean (SD) 263.4 (79.8) 314.6 (63.6) 290.7 (73.8) 5 high 
Median (range) 258 (164-414) 323 (228-329) 282 (164-414)  Glycine,  µmol/L 
Normal range   111-327  
Mean (SD) 320.6 (64.0) 323.4 (39.4) 322.1 (50.3)  
Median (range) 300 (250-426) 330.5 (251-383) 311 (250-426)  Alanine, µmol/L 
Normal range   186-522  
Mean (SD) 26.6 (6.9) 29.1 (7.5) 27.9 (7.1)  
Median (range) 24 (17-38) 27.5 (22-46) 26 (17-46)  Citrulline, µmol/L 
Normal range   17-49  
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App.table 1: continued 
 
  Group A Group B Total Comments1 
 N 7 8 15  
Mean (SD) 14.9 (3.0) 11.8 (1.3) 13.2 (2.7)  
Median (range) 15 (9-18) 12 (10-13) 13 (9-18)  α-aminobutyric acid, µmol/L 
Normal range   8-36  
Mean (SD) 220.6 (42.7) 212.6 (27.0) 216.3 (34.1)  
Median (range) 235 (160-266) 215 (175-258) 218 (160-266)  Valine, µmol/L 
Normal range   145-313  
Mean (SD) 22.3 (10.3) 21.8 (17.0) 22.0 (13.8) 8 low 
Median (range) 22 (6-40) 29.5 (1-39) 24 (1-40)  Cystine, µmol/L 
Normal range   30-62  
Mean (SD) 20.4 (4.4) 19.5 (3.6) 20.0 (4.0)  
Median (range) 20 (14-26) 18.5 (16-26) 19 (14-26)  Methionine, µmol/L 
Normal range   14-30  
Mean (SD) 52.4 (9.6) 49.3 (6.5) 50.7 (8.0)  
Median (range) 48 (41-67) 47 (41-62) 47 (41-67)  Isoleucine, µmol/L 
Normal range   35-83  
Mean (SD) 95.6 (12.1) 98.9 (17.3) 97.3 (14.8)  
Median (range) 95 (74-112) 101 (79-129) 95 (74-129)  Leucine, µmol/L 
Normal range   69-161  
Mean (SD) 57 (20.7) 47.4 (15.0) 51.9 (17.9) No-one low 
Median (range) 53 (39-100) 39 (35-73) 52 (35-100) 1high Tyrosine, µmol/L 
Normal range   28-76  
Mean (SD) 618.4 (374.3) 379.8 (180.0) 491.1 (302.3) All high! 
Median (range) 505 (187-1315) 325 (115-660) 401 (115-1315)  Phenylalanine, µmol/L 
Normal range   32-68  
Mean (SD) 0 0 0  
Median (range) 0 0 0  
Homocystine 
free, 
µmol/L 
Normal range   0  
Mean (SD) 71.3 (6.0) 69.3 (7.0) 70.2 (6.4)  
Median (range) 73 (61-80) 68.5 (58-81) 69 (58-81)  Histidine, µmol/L 
Normal range   64-116  
Mean (SD) - - -  
Median (range) 2 (trace-5) 2 (trace-4) 2 (trace-5)  
3-metyl-
histidine 
µmol/L2 
Normal range   1-5  
Mean (SD) - - -  
Median (range) 3 (trace-20) 3.5 (2-23) 3 (trace-23)  
1-metyl-
histidine 
µmol/L2 
Normal range   0-20  
Mean (SD) 34.9 (11.4) 36.9 (11.1) 35.9 (10.9)  
Median (range) 31 (27-60) 34 (20-56 33 (20-60)  Tryptophane, µmol/L 
Normal range   19-59  
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App.table 1: continued 
 
   Group A Group B Total Comments1 
 N 7 8 15 
 
 
 
Mean (SD) 62.7 (20.0) 65.4 (20.1) 64.1 (19.3) 2 high, both 
Median (range) 62 (38-102) 59 (40-99) 62 (38-102) improperly Ornithine, µmol/L 
Normal range   24-84 prepare
 
d 
Mean (SD) 171.9 (19.2) 193.3 (26.7) 183.3 (25.2)  
Median (range) 169 (135-192) 188.5 (162-230) 176 (135-230)  Lysine, µmol/L 
Normal range   128-248 
 
 
Mean (SD) 54.7 (9.2) 87.4 (29.9) 72.1 (27.7) 2 improperly 
Median (range) 53 (44-65) 92.5 (50-137) 64 (44-137) prepared, Arginine, µmol/L 
Normal range   40-128  
1 The terms low and high refer to results lower or higher than the laboratory’s normal range. 
2 For the amino acids hydroxyproline, 3-metylhistidine and 1-metylhistidine some results were 
given as trace instead of definite values; mean and standard deviation could thus not be 
calculated. 
 
 
 
• All phenylalanine analyses were high, as expected. 
• Tyrosine will fall to subnormal levels in PKU if protein substitute is not taken, 
therefore the substitute is fortified with extra tyrosine. One subject was taking a 
substitute with larger amount of tyrosine than the other participants, resulting in a high 
tyrosine level. 
• Glutamic acid easily transforms into glutamine, analyzed results are therefore often 
added and seen as one, the result should be <846 µmol/L. The results over are all in 
the normal range, when adding glutamine and glutamic acid. 
• In a catabolic state glycine will rise and valine will fall to subnormal lavels. Five 
blood tests had elevated glycine, one >400 µmol/L, but valine was normal for all. 
Elevated glycine can be a sign of a beginning catabolic state, may be due to a long 
overnight fast. 
• Low valine would implicate a catabolic state and that protein substitute was not taken 
as prescribed. No subject had low valine in this study. 
• Ornithine will rise if the test is not properly prepared within a short time; 
simultaneously arginine and cystine will tend to fall, the high ornithine observations 
in the study could be explained due to improper preparation leading to these 
reactions.  
• For two subjects, analyses were done from serum instead of heparine plasma, 
resulting in false high answers for aspartic acid, serine and arginine 
 
 
Interpretation of amino acid analyses were done in cooperation with senior consultant Berit 
Woldseth, MD, Department of Medical Biochemistry at Rikshospitalet. 
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Appendix table 2: Blood analyses 
(Amino acids in appendix table 1) 
  Group A Group B Total Comments1 
N 7 6 13 All normal  
Mean (SD) 13.9 (0.8) 13.8 (0.8) 13.8 (0.76)  
Median (range) 13.5 (13.2-15.2) 13.6 (12.9-15.2) 13.5 (12.9-15.2)  
B-Haemo-
globin 
g/dl 
Normal range   F: 11.7-17 M: 13.4-17  
N 7 5 12 Most in low 
Mean (SD) 41.3 (1.6) 41.2 (4.7) 41.3 (3.1) normal range  
Median (range) 41 (39-44) 39 (38-49) 41 (38-49)  
B-Hemato-
crite, 
% 
Normal range   F: 35-46 M:40-50  
N 6 10 16 1 low 
Mean (SD) 18.8 (6.2) 16.2 (4.3) 17.2 (5.1) Most in low 
Median (range) 18.5 (11-27) 16.5 (7-21) 17 (7-27) normal range  
P-Iron, 
µmol/L 
Normal range   F & M: 9-34  
N 6 7 13 Most in low 
Mean (SD) 2.7 (0.5) 2.7 (0.3) 2.7 (0.4) normal range  
Median (range) 2.9 (1.8-3.2) 2.7 (2.3-3.1) 2.8 (1.8-3.2)  
P- 
Transferrin, 
g/L 
Normal range   F & M: 2.2-3.9  
N 6 7 13 Most in low 
Mean (SD) 0.27 (0.06) 0.26 (0.05) 0.27 (0.05) normal range  
Median (range) 0.27 (0.19-0.34) 0.26 (0.18-0.32) 0.26 (0.18-0.34)  
P-
Transferrin 
saturation 
Normal range   F: .1-.5 M:.15-.57  
N 6 10 16 1 low 
Mean (SD) 83.8 (50.6) 66.3 (72.7) 72.9 (64.1)  
Median (range) 64 (32-147) 45 (9-257) 52.5 (9-257)  
P- Ferritin, 
µg/L 
Normal range   F:10-167 M: 29-383  
N 6 8 14  
Mean (SD) 31.8 (8.9) 37.6 (4.9) 35.1 (7.2)  
Median (range) 30 (22-44) 38 (28-43) 37 (22-44)  
S-Carnitine 
free,  
µmol/L 
Normal range   F: 19-50 M: 28-50  
N 6 8 14  
Mean (SD) 39.5 (9.9) 45.6 (6.8) 43 (8.5)  
Median (range) 39 (26-51) 45.5 (35-54) 43.5 (26-54)  
S-Carnitine 
total, 
µmol/L 
Normal range   F: 20-58 M: 34-59  
N 7 9 16  
Mean (SD) 3.6 (0.7) 4.2 (0.6) 3.9 (0.7)  
Median (range) 3.5 (2.6-4.7) 4.1 (3.4-5.0) 3.8 (2.6-5.0)  
S-Urea, 
Mmol/L 
Normal range   F: 2.6-6.4 M: 3.2-8.1  
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App.table 2:continued 
 
   Group A Group B Total Comments1 
N 7 10 17 
 
 
Mean (SD) 66.1 (12.8) 63.5 (10.7) 64.6 (11.3)  
Median (range) 62 (52-82) 63.5 (46-83) 62 (46-83)  
S-
Creatinine, 
µmol/L2 
Normal range   F: 50-90 M: 60-105  
N 6 10 16  
Mean (SD) 0.82 (0.03) 0.91 (0.09) 0.87 (0.08)  
Median (range) 0.83 (0.76-0.85) 0.89 (0.82-1.07) 0.85 (0.76-1.07)  
S-
Magnesium 
mmol/L 
Normal range   F&M: 0.71-0.94  
N 7 10 17 1 low 
Mean (SD) 464.3 (258.7) 666.4 (188.1) 583.2 (235.6) 5 high 
Median (range) 490 (110-915) 672.5 (440-1030) 580 (110-1030)  
S- Vitamin 
B12,  
pmol/L 
Normal range   F&M: 160-710  
N 7 6 13 10 high 
Mean (SD) 1846.4 (1006.7) 1601.3 (447.1) 1733.3 (778.6)  
Median (range) 1950 (605-3165) 
1790 (793-
1963) 
1870 (605-
3165)  
ER-Folate, 
nmol/L 
Normal range   F&M: 390-1140  
N 7 8 15 13 high 
Mean (SD) - - -  
Median (range) >54.4 (22.3-54.4) 50.5 (34->54.4) 53 (22.3->54.4)  
S- Folate3, 
nmol/L 
Normal range   F&M:7.1-27  
N 7 7 14  
Mean (SD) 12.1 (1.1) 14.1 (1.7) 13.1 (1.7)  
Median (range) 12 (11-14) 14 (12-17) 13 (11-17)  
S-Zinc,  
µmol/L 
Normal range   F&M: 10-16  
N 7 10 17 4 >5.0 
Mean (SD) 4.3 (1.2) 5.0 (1.2) 4.7 (1.2) no known heart 
Median (range) 3.9 (3.2-6.5) 4.8 (3.9-7.8) 4.6 (3.2-7.8) disease 
P-
Cholesterol
mmol/L 
Normal range   30-49 y: 3.3-6.9  
N 7 10 17  
Mean (SD) 1.4 (0.6) 1.3 (0.3) 1.3 (0.4)  
Median (range) 1.1 (0.9-2.3) 1.3 (0.9-1.8) 1.2 (0.9-2.3)  
P- HDL-
Cholesterol
mmol/L 
Normal range   F: 1.0-2.7 M: 0.8-2.1  
N 6 10 16 6 >3.0,  
Mean (SD) 2.6 (0.6) 3.2 (1.0) 3.0 (0.9) no known heart 
Median (range) 2.5 (1.9-3.8) 3.0 (2.4-5.8) 2.8 (1.9-5.8) disease 
P- LDL 
Cholesterol
mmol/L 
Normal range   30-49 y: 1.9-4.8  
N 7 10 17 2 high 
Mean (SD) 1.8 (1.7) 1.8 (1.2) 1.8 (1.4)  
Median (range) 1.0 (0.7-5.6) 1.6 (0.8-4.8) 1.4 (0.7-5.6)  
P- 
Triglyceride
mmol/L 
Normal range   F&M 0:.5-2.6  
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App.table 2: continued 
 
   Group A Group B Total Comments1 
N 7 10 17 
 
 
 
Mean (SD) 45.6 (3.6) 42.7 (2.1) 43.9(3.1)  
Median (range) 47 (39-50) 42.5 (39-45) 44 (39-50)  
P- Albumin, 
g/L 
Normal range   F: 36-45 M: 36-48  
N 7 8 15 1 low 
Mean (SD) 0.30 (0.07) 0.25 (0.04) 0.27 (0.06)  
Median (range) 0.31 (0.16-0.37) 0.25 (0.19-0.33) 0.27 (0.16-0.37)  
S- 
Prealbumin, 
g/L 
Normal range   F: 0.23-0.39 M: 0.26-0.45  
N 6 9 15  
Mean (SD) 0.33 (0.09) 0.28 (0.06) 0.30 (0.07)  
Median (range) 0.31 (0.25-0.47) 0.27 (0.22-0.38) 0.29 (0.22-0.47)  
S- Cerulo-
plasmin, 
g/L 
Normal range   F: 0.24-0.55 M: 0.22-0.38  
 
 
B = blood   F: female 
S = serum   M: male 
P = plasma When normal range varies according to age, only 
mid-adult values are given. 
 
 
1 The terms low and high refer to results lower or higher than the laboratory’s 
normal range. 
2 Estimated glomerular filtration rate (GFR) was normal >60 ml/min/1.73 m2 
for all subject with analyzed creatinine  
3 Folate in serum: 7 results were given as values >54.4 nmol/L. Geometric 
mean and standard deviation could thus not be calculated. 
 
For information on analytical methods see Laboratoriehåndbok from 
Rikshospitalet (57) 
 
Interpretation of the blood analyses were done in cooperation with senior 
consultant Per Mathisen, MD, Medical Outpatient Department at 
Rikshospitalet. 
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Appendix table 3: Intake of non-energy nutrients 
   Group A Group B Total 
 N 7 12 19 
NNR1 Nor-kost2 
Mean (SD) 54 (36) 59 (40) 57 (38)   
Median  
(Q1-Q3) 
52 
(31 – 60) 
44 
(33 – 100) 
46 
(31 – 89)  291 
Cholesterol, 
mg/d 
Min-max 17 – 128 0 – 133 0 – 133   
Mean (SD) 1157 (285) 1246 (206) 1213 (235)   
Median  
(Q1-Q3) 
1124 
(942 – 1450) 
1201 
(1095 – 1336) 
1196 
(1029 – 1355) 800 900 
Calcium, 
mg/d 
Min-max 765 – 1509 1028 – 1746 765 – 1746   
Mean (SD) 2190 (619) 2453 (654) 2356 (637)   
Median  
(Q1-Q3) 
2466 
(1782 – 2574) 
2409 
(1987 – 3010) 
2466 
(1984 – 2644)   
Sodium, 
mg/d 
Min-max 941 – 2626 1310 – 3446 941 – 3446   
Mean (SD) 2677 (822) 3381 (735) 3122 (823)   
Median  
(Q1-Q3) 
2663 
(1963 – 3078) 
3368 
(2839 – 4145) 
3078 
(2632 – 3552)   
Potassium, 
mg/d 
Min-max 1721 – 4214 2185 – 4530 1721 – 4530   
Mean (SD) 1200 (412) 1486 (262) 1380 (344)   
Median  
(Q1-Q3) 
1309 
(988 – 1493) 
1455 
(1291 – 1589) 
1410 
(1215 – 1581)   
Phosphorus
mg/d 
Min-max 431 – 1719 1147 – 2147 431 – 2147   
Mean (SD) 482 (140) 586 (84) 548 (116)   
Median  
(Q1-Q3) 
511 
(436 – 583) 
567 
(529 – 640) 
549 
(502 – 626) 280/350  
Magnesium, 
mg/d 
Min-max 209 – 640 458 – 758 209 – 758   
Mean (SD) 34 (10) 43 (8) 40 (10)   
Median  
(Q1-Q3) 
33 
(26 – 46.2) 
42 
(36.8 – 49.2) 
40 
(32.9 – 46.8) 15/9 10.8 Iron, mg/d 
Min-max 25 – 48 30 – 57 25 – 57   
Mean (SD) 20 (4) 24 (3) 22 (4)   
Median  
(Q1-Q3) 
19 
(16 – 23.1) 
23 
(21.4 – 24.1) 
22 
(19.3 – 24) 7/9  Zinc, mg/d 
Min-max 14 – 25 19 – 32 14 – 32   
Mean (SD) 76 (20) 86 (15) 82 (17)   
Median  
(Q1-Q3) 
79 
(57 – 95) 
85 
(79 – 91) 
84 
(73 – 92) 40/50  
Selenium, 
µg/d 
Min-max 43 – 100 65 – 124 43 – 124   
Mean (SD) 1680 (365) 2443 (627) 2162 (654)   
Median  
(Q1-Q3) 
1840 
(1239 – 1966) 
2286 
(1969 – 3008) 
2002 
(1719 – 2598) 700/900 1500 
Vitamin A3, 
µg/d 
Min-max 1093 – 2002 1658 – 3507 1093 – 3507   
Mean (SD) 17.2 (6) 18.7 (5.5) 18.1 (5.6)   
Median  
(Q1-Q3) 
18.4 
(12.4 – 21.1) 
18.4 
(14.6 – 20.0) 
18.4 
(14.3 – 20.1) 7.5 4.8 
Vitamin D4, 
µg/d 
Min-max 9.1 – 26.9 10.5 – 31.8 9.1 – 31.8   
 
 92 
App.table 3: continued 
   Group A Group B Total 
 N 7 12 19 
NNR1 Nor-kost2 
Mean (SD) 20 (6) 22 (9) 21 (8)   
Median  
(Q1-Q3) 
21 
(16.3 – 24.1) 
23 
(14.3 – 29.8) 
22 
(14.7 – 25.0) 8/10  
Vitamin E5, 
mg/d 
Min-max 11 – 28 8 – 38 8 – 38   
Mean (SD) 2.6 (0.4) 3 (0.5) 2.9 (0.5)   
Median  
(Q1-Q3) 
2.6 
(2.2 – 3.0) 
3.0 
(2.6 – 3.5) 
2.9 
(2.5 – 3.1) 1.1/1.4 1.4 
Thiamin, 
mg/d 
Min-max 2.2 – 3.1 2.2 – 3.6 2.2 – 3.6   
Mean (SD) 2.8 (0.5) 3.2 (0.5) 3.0 (0.5)   
Median  
(Q1-Q3) 
2.7 
(2.3 – 3.4) 
3.1 
(2.8 – 3.6) 
2.9 
(2.6 – 3.5) 1.3/1.7 1.7 
Riboflavin, 
mg/d 
Min-max 2.2 – 3.5 2.4 – 3.9 2.2 – 3.9   
Mean (SD) 46 (13) 54 (9) 51 (11)   
Median  
(Q1-Q3) 
46 
(33 – 57) 
55 
(47 – 61) 
54 
(46 – 58) 15/19 17 
Niacin6, 
mg/d 
Min-max 29 – 64 36 – 66 29 – 66   
Mean (SD) 3.6 (0.6) 4.2 (0.6) 4.0 (0.7)   
Median  
(Q1-Q3) 
3.3 
(3.0 – 4.1) 
4.1 
(3.8 – 4.7) 
4.0 
(3.4 – 4.5) 1.2/1.6  
Vitamin B6 7, 
mg/d 
Min-max 2.9 – 4.5 3.4 – 5.4 2.9 – 5.4   
Mean (SD) 715 (273) 888 (142) 824 (211)   
Median  
(Q1-Q3) 
706 
(381 – 922) 
870 
(792 – 969) 
866 
(706 – 964) 300  Folate
8, µg/d 
Min-max 342 – 1065 656 – 1174 342 – 1174   
Mean (SD) 211 (79) 281 (144) 255 (126)   
Median  
(Q1-Q3) 
203 
(161 – 266) 
239 
(203 – 298) 
222 
(183 – 266) 75 120 
Vitamin C9, 
mg/d 
Min-max 97 – 346 178 – 696 97 – 696   
Mean (SD) 1.3 (0.6) 1.8 (0.3) 1.6 (0.4)   
Median  
(Q1-Q3) 
1.4 
(0.7 – 1.9) 
1.7 
(1.6 – 1.9) 
1.7 
(1.4 – 1.9)   
Energy from 
protein 
substitute, 
MJ/d Min-max 0.4 – 1.9 1.3 - 2.1 0.4 – 2.1   
1 NNR: Nordic Nutrition Recommendations 2004 (44) 
Only adult recommendations are noted 
Gender differences noted as female/male.  
2 Norkost: Johansson & Solvoll (63) 
 
3 Vitamin A: Retinol equivalents = retinol + 1/6 β-carotene 
4 Vitamin D: Cholecalciferol (D3) + ergocalciferol (D2) 
5 Vitamin E: α-tocoferol 
6 Niacin: Nicotinic acid + nicotinamid  
7 Vitamin B6: Pyridoxin + pyridoxal + pyridoxamine 
8 Folate: Folic acid + derivatives  
9 Vitamin C: Ascorbic acid + dehydroascorbic acid 
 
Food intake was calculated on Mat på Data 4.a (54) 
Norwegian food composition table from 2001 (55)
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Appendix 4 
 Samtykkeerklæring: 
 
 
Hvis du vil delta i studien ”Diettbehandling for voksne med sent diagnostisert PKU” 
skal du skrive under og sende dette arket tilbake til oss i utfylt stand.  
Returner denne samtykkeerklæringen innen 20. mars. 
Bruk vedlagte frankerte konvolutt. 
 
Les gjennom det vedlagte informasjonsbrevet før du bestemmer deg. 
Hvis du har spørsmål om studien, ta kontakt med Ingrid Wiig på telefon 23 07 53 40  
eller på e-post ingrid.wiig@rikshospitalet.no 
 
Deltakelse i studien er frivillig og kan når som helst og uten begrunnelse trekkes 
tilbake.  
 
 
 
 
 
 
Dato: ____________ Sted: ______________________________________ 
 
 
Signatur: ________________________ 
 
 
Adresse: ________________________________________________________ 
 
________________________________________________________________ 
 
 
Telefon: ____________ 
 
 
 
 
 
 
 
 
Denne samtykkeerklæringen sendes til: 
 
Ingrid Wiig 
Senter for sjeldne diagnoser 
Rikshospitalet-Radiumhospitalet HF 
0027 Oslo 
 
Den kan også sendes på fax: 22 96 56 59 
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Appendix 5 
 Medisinsk Service 1 
 Senter for sjeldne 
diagnoser 
 
Deres ref:  
Vår ref:  
Dato: 10.03.2006 
 
Postadresse: 
0027  OSLO 
 
Besøksadresse: 
Forskningsvn. 3b 
 
Sentralbord: 23 07 00 00 
Dir. linje: 23 07 53 40 
Telefaks: 23 07 53 50 
 
 
 
 
Org.nr. NO 987 399 708 MVA
 
 
 
Informasjon om studie vedrørende diettbehandling for voksne med PKU 
 
Vi ønsker å invitere deg til å delta i en studie for å kartlegge diettbehandlingen hos voksne som har PKU og 
hjerneskade.  
 
Man vet i dag mye om hvordan PKU-dietten bør være, men mindre om hvordan den virkelig gjennomføres. Å få 
slik kunnskap er viktig blant annet for å kunne gi best mulig råd og oppfølging til hver enkelt.  
I studien ønsker vi også å kartlegge hvilken hjelp du og andre med PKU mottar.  
 
Hva vil studien innebære for deg? 
• I studien vil du bli spurt om å gjøre en kostregistrering.  
Det betyr at du skal notere alt du spiser og drikker i fire dager. Du vil få nøyaktig beskjed om hvordan 
kostregistreringen skal utføres før du starter. Du vil få eget hefte å registrere i og du kan låne vekt hvis du ikke 
har det selv.  
 
• I forbindelse med registreringen vil du bli intervjuet.  
I tillegg ønsker vi å intervjue en av dine pårørende eller en fagperson som jobber for deg. Intervjuet består av 
spørsmål om hvordan dietten ordnes, når du fikk diagnosen PKU og hva slags støtte du mottar. Informasjon til 
pårørende og fagfolk er blant papirene du har fått tilsendt. 
 
• Du skal som vanlig ta blodprøver for fenylalanin (i fingeren) hver måned.  
Vi ber om å få kopi av disse blodprøvesvarene.  
I tillegg vil du innkalles til Medisinsk poliklinikk ved Rikshospitalet eller til kontroll hos fastlegen din i løpet av 
våren 2006. Denne kontrollen er en del av den vanlige PKU-oppfølgingen. Vi ber om kopi av svar fra 
blodprøvene som tas ved denne kontrollen. 
 
Etter studien vil du få samtale og råd om diettbehandlingen basert på kostregistreringen din. 
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 Hvem kan delta? • For å delta må du være voksen, ha PKU og leve på PKU-diett.  
Personer som kan delta i studien har større eller mindre hjerneskade, oftest på grunn av sen PKU-diagnose 
eller utilstrekkelig behandling som barn.  
• Pårørende eller fagfolk rundt deg vil bli spurt om å bistå og bidra med nødvendig informasjon så studien kan 
gjennomføres. 
 
Om studien 
Studien er vurdert og tilrådet av Regional komité for medisinsk forskningsetikk. 
Blodprøvesvarene samles i en forskningsbiobank som opprettes for denne studien.  
Ansvarlig for studien og forskningsbiobanken er dr.med. Bengt Frode Kase, avdelingsleder ved Senter for 
sjeldne diagnoser.  
 
Studien gjennomføres av mastergradsstudent Ingrid Wiig i samarbeid med Avdeling for ernæringsvitenskap ved 
Universitetet i Oslo og Senter for sjeldne diagnoser (tidligere Senter for sjeldne sykdommer og syndromer). De 
som blir spurt om å delta er registrert ved Senter for sjeldne diagnoser.  
 
Personvern 
Alle opplysninger vil bli behandlet konfidensielt. Det vil si at kun prosjektansvarlig Bengt Frode Kase og student 
Ingrid Wiig vet hvem som deltar og hvilke opplysninger som gis. All informasjon oppbevares utilgjengelig for 
andre.  
Alle data vil være fullstendig anonymisert fra utgangen av 2007. Det betyr at når studien er ferdig vil ingen som 
leser resultatene, kunne knytte informasjonen til bestemte personer.  
 
Deltakelse i studien er frivillig, og du kan trekke tilbake samtykke når som helst og uten begrunnelse. Ved 
samtykke om deltakelse gis det også tillatelse til gjennomgang av journal ved Rikshospitalet. Du kan be om 
innsyn i data som angår deg i studien. Hvis du velger å trekke samtykket tilbake før studien er avsluttet, vil 
opplysninger og blodprøvesvar fra deg ikke inngå i resultatene fra studien. Hvis du trekker deg fra studien, kan 
du be om at blodprøver ødelegges uten å bli analysert.  
 
Dette brevet inneholder informasjon og er en invitasjon til å delta i studien. 
Hvis du ønsker å delta, ber vi om at du skriver under og sender inn den vedlagte samtykkeerklæringen i 
vedlagte konvolutt, innen 20. mars.  
 
Ved spørsmål, kontakt Ingrid Wiig på telefon 23 07 53 40, på mobiltelefon 976 70 994, eller på e-post: 
ingrid.wiig@rikshospitalet.no 
 
 
 
Vennlig hilsen 
 
 
 
Bengt Frode Kase 
Avdelingsleder, dr.med. 
    
 
 
Vedlagt: 
Samtykkeerklæring og informasjon om studien til pårørende og fagfolk. 
 101
Appendix 6 
 Medisinsk Service 1 
 Senter for sjeldne 
diagnoser 
 
Deres ref:  
Vår ref:  
Dato: 10.03.2006 
 
Postadresse: 
0027  OSLO 
 
Besøksadresse: 
Forskningsvn. 3b 
 
Sentralbord: 23 07 00 00 
Dir. linje: 23 07 53 40 
Telefaks: 23 07 53 50 
 
 
 
 
Org.nr. NO 987 399 708 MVA
 
 
Informasjon til pårørende og fagfolk om studie  
vedrørende diettbehandling for voksne med PKU 
 
Dette brevet sendes ut sammen med informasjon og forespørsel om deltakelse i studien til personer med PKU.  
Vi ønsker å gjennomføre en studie for å kartlegge diettbehandlingen hos voksne som har PKU og hjerneskade. 
Man vet i dag mye om hvordan PKU-dietten bør være, men mindre om hvordan den gjennomføres til daglig. 
Spesielt lite kunnskap har man om hvordan dietten gjennomføres hos voksne med hjerneskade eller sen 
behandlingsstart. Å innhente kunnskap om dette er viktig blant annet for å tilpasse råd og oppfølging til hver 
enkelt.  
Studien vil også kartlegge hvilken hjelp som ytes til brukergruppen. 
Flere av de forespurte har ikke selv mulighet til å samtykke eller avslå deltakelse i studien.  
Gjennomføring av studien er derfor avhengig av velvillighet og støtte hos pårørende og fagfolk. 
 
Hva vil studien innebære? 
• Studien omfatter en kostregistrering.  
Alt som spises og drikkes i fire dager skal noteres. Det vil bli gitt nøyaktig beskjed om hvordan 
kostregistreringen skal utføres før start. Det sendes ut eget hefte å registrere i og vekt kan lånes hvis det ikke 
er tilgjengelig.  
• I forbindelse med registreringen vil en pårørende og/eller fagperson bli intervjuet.  
I intervjuet innhentes informasjon relatert til PKU, behandlingen og eventuelle støttetiltak. Der det er mulig vil 
også studiedeltakeren/informanten selv bli intervjuet. 
• Blodprøver for fenylalanin (i fingeren) skal tas som vanlig hver måned.  
Vi ber om få innhente kopi av disse blodprøvesvarene. I tillegg vil deltakeren bli innkalt til kontroll ved 
Medisinsk poliklinikk ved Rikshospitalet, eller bli spurt om å foreta tilsvarende kontroll hos fastlege. Denne 
kontrollen er en del av oppfølgingen ved PKU. Regional komité for medisinsk forskningsetikk har åpnet for at 
vi kan be om kopi av blodprøvesvar som inngår i oppfølging og legekontroll ved PKU også der personen selv 
ikke kan gi samtykke om deltakelse. Blodprøvesvarene som samles i studien vil inngå i en såkalt biobank, all 
informasjon i biobanken vil slettes etter studien. 
 
Utenom rutinemessige fenylalaninprøver og legekontroll, vil studien ikke påvirke hverdagen til de dårligst 
fungerende i pasientgruppen. 
Etter studien vil det bli gitt tilbakemelding og råd basert på kostregistrering og blodprøveresultat. 
 
Hvem kan delta? 
• Voksne med PKU som lever på PKU-diett.  
Personer som kan delta i studien har større eller mindre hjerneskade, oftest på grunn av sen diagnose eller 
utilstrekkelig behandling som barn.  
• Pårørende eller fagfolk vil bli spurt om å bistå og bidra med nødvendig informasjon så studien kan 
gjennomføres. 
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Ansvarlig for gjennomføring  
Studien er vurdert og tilrådet av Regional komité for medisinsk forskningsetikk. Blodprøvesvarene samles i en 
forskningsbiobank som opprettes for denne studien. Ansvarlig for studien og forskningsbiobanken er dr.med 
Bengt Frode Kase, avdelingsleder ved Senter for sjeldne diagnoser. 
Studien gjennomføres av mastergradsstudent Ingrid Wiig i samarbeid mellom Avdeling for ernæringsvitenskap 
ved Universitetet i Oslo og Senter for sjeldne diagnoser (tidligere Senter for sjeldne sykdommer og syndromer).  
Alle som blir spurt om å delta er registrert ved Senter for sjeldne diagnoser.  
 
Personvern 
Alle opplysninger vil bli behandlet konfidensielt. Kun prosjektansvarlig Frode Kase og mastergradstudent Ingrid 
Wiig vet hvem som deltar og hvilke opplysninger som gis. All informasjon oppbevares utilgjengelig for andre og 
vil være fullstendig anonymisert fra utgangen av 2007.  
 
Deltakelse er frivillig, og studiedeltakerne kan trekke tilbake samtykket sitt når som helst og uten begrunnelse. 
Hvis samtykket trekkes tilbake før studien er avsluttet, vil opplysninger og blodprøvesvar fra personen ikke 
brukes i studien. Man kan da også be om at blodprøver ødelegges uten å bli analysert. Ved deltakelse gis det 
samtidig tillatelse til gjennomgang av journal ved Rikshospitalet. Deltakerne kan be om innsyn i innsamlet data 
vedrørende egen person. 
 
For personer som ikke selv kan gi informert samtykke til deltakelse, ber vi om at fagfolk og/eller pårørende 
vurderer deltakelse i studien på vegne av personen med PKU. Fagfolk vil bli involvert i kostregistrering og 
intervju, mens deltakeren selv følger diettbehandlingen som vanlig.  
Ved spørsmål, kontakt Ingrid Wiig på telefon 23 07 53 40, på mobiltelefon 976 70 994,                
eller på e-post: ingrid.wiig@rikshospitalet.no 
 
Vi ber om at svarslippen under returneres i utfylt stand i vedlagte konvolutt, innen 20.mars 2006. 
 
 
Vennlig hilsen 
 
 
Bengt Frode Kase 
Avd.leder, dr.med 
 
--------------------------------------------------------------------------------------------------------------------------------------- 
Svarslipp: returner innen 20.3.06, til Ingrid Wiig, Senter for sjeldne diagnoser, Rikshospitalet-
Radiumhospitalet HF, 0027 Oslo 
 
Vi/jeg kan bidra med informasjon/gjennomføre kostregistrering til studien ”Diettbehandling for voksne med sent 
diagnostisert PKU” på vegne av pasient med PKU. 
 
Navn på pasient: ___________________________________________________________________ 
 
Navn på kontaktperson (-er): _________________________________________________________ 
 
Adresse:__________________________________________________________________________ 
 
_________________________________________________________________________________ 
 
Telefon: __________________ 
 
Underskrift: _______________________________________________________________________ 
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Appendix 7  
Intervjuskjema – bruker – pårørende – hjelper
Samme punkter og spørsmål brukt til begge kategorier, bortsett fra siste to sider der 
spørsmålene var ulike – her er mellomrom og plass til notater fjernet for å redusere 
sidetallet. 
Deltakernummer:        Dato:  
 
Innledning, kort 
Forklare hensikten med intervjuet: 
 Finne ut hvordan dietten gjennomføres i det daglige  
Forklare hva jeg ønsker å få informasjon om: 
 Hvordan man ordner seg praktisk 
Hvor mye bistand som gis, i form av tiltak fra kommunen/boligen og fra private hjelpere som 
familie 
Om man mottar trygdeytelser for dietten 
Forklare hvordan dataene vil inngå i studien: 
Ingen vil kunne kjennes igjen, andre skal ikke gjenkjenne enkeltpersoner når resultatene leses
Ingen andre får tilgang til svarene som gis  
 
De fleste spørsmålene vil kun kreve korte svar, men andre kan kreve at du tenker 
deg mer om og trenger flere ord – ikke vær redd for å bruke tiden du trenger 
 
Bakgrunnsdata 
Boforhold i dag:       
alene   foreldre  ektefelle/samboer egne barn andre (relasjoner) 
 egen bolig  tilknyttet pårørendes bolig    
kommunal bolig  bolig med fagfolk på dagtid  døgnbemanning 
Hvor lenge hatt nåværende bolig? 
Tidligere boforhold eller opphold i institusjon, kort sammendrag: 
 
Faste aktiviteter eller jobb på dagtid: 
 Arbeid: type    antall dager per uke  vernet eller veiledet 
Annet organisert dagtilbud: 
Måltider i løpet av arbeidsdag/dagtilbud:  matpakke/kantine/felles matlaging 
 Fritidsaktiviteter/hobbier:  
 Organisert/sammen med andre      hyppighet 
Forekommer det servering eller behov for å spise i løpet av denne tiden: 
Lønn/uføretrygd 
Trygdeytelser og annen økonomisk bistand utover eventuell uføretrygd 
Grunnstønad  Hjelpestønad  Annet 
 
Hjelp til daglige gjøremål som husarbeide, dietten, annet … 
Hjelp fra pårørende, beskriv:    Fast organisert eller etter behov 
Tilbud fra kommunen, beskriv:    timer/uke 
Fast kontaktperson i kommunen/boligen?  ja/nei 
Støttekontakt?      timer/uke    
Kun til fritidsaktiviteter/hjelper støttekontakten også med diett, andre oppgaver? 
Funksjon og behov for hjelp/tiltak ellers (fortrinnsvis til pårørende/fagpersoner):  
Hvem       hyppighet 
Årsaken til eller begrunnelsen for disse tiltakene 
Ansvarsgruppe?  ja/nei    
hvem er med   møtefrekvens 
Individuell plan?  ja/nei 
Hjelpeverge?  ja/nei       
Tiltak som er søkt, men avslått:    Begrunnelse som ble gitt 
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Diettbehandlingen  
Hvem styrer gjennomføringen av dietten til daglig?    selv/fagfolk/pårørende
Hvordan organiseres menyer/måltider/matlaging, beskriv 
Hvor mye PKU-mat lages i stand fra grunnen/etter egne oppskrifter 
Baking     middagsretter 
lite/det meste/alt   lite/det meste/alt 
Hva mottas av hjelp i forbindelse med den daglige gjennomføringen av dietten, beskriv: 
Spiseferdighet: selvstendig  verbal/håndledning mating  
 Behov for tilrettelagt konsistens  ja/nei 
Dietten i sosiale sammenhenger 
Fravikes dietten i noen sammenhenger? ja/nei   
I tilfelle hvor ofte: 
>1/uke  1/uke  2-3/måned  1/måned sjeldnere 
I tilfelle når: 
festdager hjemme/borte fritidsaktiviteter  kafebesøk  ferier/turer
 kun på egen hånd  sammen med hjelper 
Brukes lister og vekt for å måle opp porsjoner/enheter:  ja/nei   
hva veies   
Holdes det nøyaktig regnskap over phe-inntak? ja/nei 
Andre ting som er viktige for å mestre dietten, beskriv: 
 
Proteinerstatning 
Type(-r)        mengde pr dag   
Hvordan tas erstatningen?  antall ganger for dagen:  før/i/etter måltidet  
Er den grei å ta (smaksmessig, mengdemessig), beskriv     
Hvordan ordnes resept og bestilling, beskriv  
 
Bruk av spesialprodukter 
Anskaffelse: butikk/postordre      hvem: selv/fagfolk/pårørende  
Hvilke proteinreduserte produkter brukes jevnlig:  
meltyper  ferdige brød   annen bakst   pasta/ris 
PKU-melk   fløteerstatning   eggerstatning   snacks/godter
Annet, beskriv: 
 
Toleranse for fenylalanin 
Phe-inntak:  Fast mengde hver dag?   mg/dag:  
Anslåtte mengder?   
Behandlingsmål for den enkelte, området for serum-phe du prøver å holde, umol/l:   
Hvor enkelt er det å holde disse målene, beskriv: 
Merker du om kostendringer påvirker phe-verdi i blodet: ja/nei 
Hvor fort merkes ev endring?  Samme dag/ved diettavvik over flere dager/merker ikke forskjell 
Andre årsaker til endringer i serum-phe enn kosten, beskriv: 
 
Rutinemessige blodprøver 
Hvor ofte      hvor   
Forhold rundt prøvetaking, beskriv kort: 
 Tas prøven fastende?    Ev hvor lenge etter siste måltid? 
 
Medikamenter utenom proteinerstatningen: 
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PKU - diagnostisering - behandling 
 
Egne erfaringer vedrørende diettens effekt Kun bruker selv  
Først perioder uten diett/med dårlig diettoppfølging, så med diett. Jeg nevner 
områder som ofte påvirkes av dietten, bruk egne ord (regn med å forklare begrepene): 
Fysisk/bevegelsesmessig 
Oppmerksomhet/konsentrasjon  
Kommunikasjon med andre/sosialt samvær 
Humørsvingninger  
Selvstendighet/initiativ 
Ferdigheter/mestringsfølelse 
Psykiske vansker     
Uro i kroppen  
Smerter/kroppslige plager 
Søvn  
Hud 
Kroppslukt 
Vi har snakket mye om hvordan dietten gjennomføres til daglig og hvilken støtte og 
hjelp som gis. Jeg ønsker å få noe mer informasjon rundt selve diagnosen, og om 
behandlingen synes å ha effekt. 
Forhold rundt diagnostisering for PKU?  
Når ble diagnosen satt    
Når ble diettbehandlingen startet: 
Behandling fra diagnosetidspunkt?   Senere behandlingsstart? 
Har det vært opphold i diettbehandlingen:     
Hvor lenge har diettbehandlingen vart (i denne omgangen):  
Hvor ble den startet      oppfølgingsrutiner, beskriv kort  
Hvorfor startet ble diettbehandlingen startet på nytt, fortell kort:  
 
Herfra har skjemaet ulike spørsmål til bruker selv og pårørende/hjelper. 
1 – til bruker: 
Annet  
 
Egne erfaringer Med diett.   
Fysisk/bevegelsesmessig 
Oppmerksomhet/konsentrasjon  
Kommunikasjon med andre/sosialt samvær 
Humørsvingninger  
Selvstendighet/initiativ 
Ferdigheter/mestringsfølelse 
Psykiske vansker     
Uro i kroppen  
Smerter/kroppslige plager 
Søvn  
Hud 
Kroppslukt 
Annet     
 
Avrunding 
Bruker: Forklar med egne ord hvordan det er å følge PKU-diett i hverdagen. 
Opplever du at behandlingen er nyttig? 
Er det andre erfaringer som du gjerne vil trekke fram til slutt?  
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2 – til pårørende/hjelper: 
 
PKU-symptomer uten og med diett - Besvares av pårørende og/eller fagfolk 
(Uvisst hvor mye av dette som kan fås, avhengig av alder/utvikling, nedtegning av erfaringer … be om 
at man leter frem gamle journaler og nedtegnelser før jeg kommer – hos noen finnes RH-journal) 
Jeg ønsker å se på bakgrunnen for at man startet diettbehandlingen.  
Før behandlingsstart, hvordan var funksjonen og symptomer, jeg nevner noen 
områder som ofte påvirkes, gi eksempler: 
Fysisk/motorisk      Nevrologisk     
Epilepsi      Medisinske forhold ellers 
Adferd       Kommunikasjon/sosial adferd 
Kognitiv funksjon     Psykiske vansker 
Humørsvingninger     Søvn  
Uro       Aggressivitet/selvskading 
Hud       Kroppslukt 
Fordøyelse      Tenner og munn 
Oppmerksomhet/konsentrasjon    Språk 
Selvstendighet/initiativ     Evne til å lære nye ferdigheter 
Annet 
 
Med diett, er noen av symptomene over endret? Jeg bruker de samme punktene som 
over.  
Fysisk/motorisk      Nevrologisk     
Epilepsi      Medisinske forhold ellers 
Adferd       Kommunikasjon/sosial adferd 
Kognitiv funksjon     Psykiske vansker 
Humørsvingninger     Søvn  
Uro       Aggressivitet/selvskading 
Hud       Kroppslukt 
Fordøyelse      Tenner og munn 
Oppmerksomhet/konsentrasjon    Språk 
Selvstendighet/initiativ     Evne til å lære nye ferdigheter 
Annet 
Hva endret seg raskt, hva tok tid?    Pågår det endringer fremdeles? 
 
Til fagfolk som har deltatt i e-læringsprosjektet 
Har kurset ført til endringer i brukers diettopplegg? Ja/nei 
  I matvarevalg/proteinerstatningen/tilberedning/planlegging/organisering 
Hvis ja, beskriv  
Er det sett forskjell i fenylalaninverdier?    Ja/nei 
Er det sett forskjell i brukers adferd/velvære/symptomer? Ja/nei 
Har kurset medført holdningsendringer overfor dietten blant personalet? Ja/nei  
 
Avrunding 
Forklar med egne ord hvordan det er å bistå i gjennomføringen eller være ansvarlig 
for dietten i hverdagen. 
Opplever du at behandlingen er nyttig? 
Er det andre erfaringer som du gjerne vil trekke fram til slutt?  
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Appendix 8 
 
 
Kostregistrering – PKU-diett 
 
Ved spørsmål kontakt Ingrid Wiig. Telefon: 23 07 53 48 eller 976 70 994.  
E-post ingrid.wiig@rikshospitalet.no  
 
Registreringen skal foretas i fire dager etter hverandre.  
Registrer alt som spises og drikkes i løpet av disse fire dagene, ikke bare det som er planlagt. 
 
Bruk de grønne heftene til noteringen.  
Et hefte per dag: noter dato og ukedag. Det er plass til kommentarer utenpå heftet. Skriv gjerne 
oppskrifter eller kommentarer vedrørende mat og drikke som er brukt på de blanke sidene. 
 
Det er viktig at registreringen blir så nøyaktig som mulig.  
Hver ting som inngår i måltidet skal noteres med type og mengde.  
Oppgi nøyaktig navn på matvarene og drikkene. Vei hvor mye som brukes eller oppgi antall desiliter.  
For PKU-melk, knekkebrød og annet med fast størrelse, er det nok å skrive opp antall stykker som er 
brukt.  
Send gjerne innpakning med varedeklarasjon på matvarer som er brukt til meg. 
Send gjerne med oppskrifter som er brukt til middag, baking osv. For retter der oppskrift er nedskrevet, 
holder det å gi oppskriften og hvor stor del av retten som ble spist. 
 
Proteinerstatning må beskrives med navn, smaksvariant og mengde.  
Noter når den tas og hvor mye som tas til hvert måltid.  
 
Noter også hva som eventuelt brukes av kosttilskudd og medikamenter.  
Send de ferdig utfylte heftene til Ingrid Wiig etter registreringen. Bruk vedlagte konvolutt. 
 
Eksempel på registrering: 
 
 
Måltidstype 
Klokkeslett Spisested  Ikke skriv her 
LUNSJ 12.30 HJEMME  
Proteinerstatning – beskriv type Mengde  Klokkeslett   
XP MAXAMUM, APPELSIN 33 G 12.15  
Annet: f. eks. medisiner eller tilskudd Mengde   
TRAN 5 ML   
    
 
 
Er dette et vanlig måltid?  ja: X  nei:  
Matvare/rett – beskriv type og mengde Mengde Vekt Ikke skriv her 
PKU-MELK 1 KARTONG   
PROTEINFRITT BRØD, BAKT AV SEMPER-MEL 2 SKIVER 53 G  
SOFT MARGARIN, VANLIG, til 2 skiver  6 G  
SALAMI 2 ENHETER   
TOMAT ½  57 G  
PKU-VAFFEL, SE VEDLAGT OPPSKRIFT  55 G  
JORDBÆRSYLTETØY, LERØY  20 G  
SETERRØMME  15 G  
BANAN 1 ENHET 83 G  
KAFFE  2 DL  
SOLO ½ FLASKE 2,5 DL  
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Appendix 9 
 
 
Kostregistrering – PKU-diett 
Skjemaer for dag xx 
 
Navn:       Dato:   Dag: 
 
Deltakernummer: 
 
Spesielle forhold rundt mat, drikke og appetitt for denne dagen, kan noteres her: 
 
 
 
Deltakere fikk et hefte i A5-format for hver dag. 
Førstesiden var som over – i tillegg var det 8 sider for registrering, utformet som skjemaet under. 
Dette ga plass for å skrive opp alle matvarer til måltidene, inklusive mellommål  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Registreringsskjema 
 
Måltidstype Klokkeslett Spisested  Ikke skriv her 
    
Proteinerstatning – beskriv type Mengde  Klokkeslett   
    
Annet: f.eks. medisiner eller tilskudd Mengde   
    
    
 
Er dette et vanlig måltid? ja:   nei:  
Matvare/rett – beskriv type og mengde Mengde Vekt Ikke skriv her 
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 Medisinsk Service 1 
Senter for sjeldne 
diagnoser 
 
Deres ref:  
Vår ref:  
Dato:  
 
Postadresse: 
0027  OSLO 
 
Besøksadresse: 
Forskningsvn. 3b 
 
Sentralbord: 23 07 00 00 
Dir. linje: 23 07 53 40 
Telefaks: 23 07 53 50 
 
 
 
 
Org.nr. NO 987 399 708 MVA
 
 
Studie om diettbehandling for voksne med sen behandlingsstart for PKU  
(fenylketonuri eller Føllings sykdom) 
 
Klinisk ernæringsfysiolog og mastergradsstudent Ingrid Wiig er i gang med en studie om 
diettbehandlingen hos voksne med PKU og hjerneskade.  
 
Primærkontakt eller andre med daglig oppfølgingsansvar, har vurdert at N.N. kan delta i studien.  
 
Bakgrunn for studien.  
Man vet i dag mye om hvordan PKU-dietten bør være, men mindre om hvordan den gjennomføres til 
daglig. Å innhente kunnskap om hvordan dietten gjennomføres og hvordan behandlingsprinsippene 
blir fulgt hos voksne med hjerneskade eller sen behandlingsstart er viktig, blant annet for å kunne 
tilpasse råd og oppfølging til hver enkelt bruker med hjelpere.  
I studien vil daglig gjennomføring av diettbehandlingen bli vurdert i forhold til anbefalinger ved PKU og 
generelle ernæringsmessige behov.  
I tillegg vil studien se på hjelp og tiltak som trengs for den enkelte pasient for å gjennomføre dietten.  
 
Det har ikke vært gjort noen tilsvarende studie på denne pasientgruppen i Norge. I utlandet har man 
sett på den medisinske effekten av behandlingen hos pasientgruppen, men studier om 
ernæringsmessige konsekvenser og det arbeidet dietten medfører er ikke publisert. 
 
Hva vil studien innebære? 
• Rutinemessige blodprøver for fenylalanin skal tas som vanlig, enten dette gjøres hos lege eller av 
personalet i boligen.  
Kopi av blodprøvesvarene innhentes til studien fra journal og screeninglaboratoriet ved Pediatrisk 
forskningsinstitutt på Rikshospitalet.  
 
• I tillegg planlegges en større blodprøve for å vurdere diettens effekt på en rekke parametre.  
 
Fra sommeren 2005 har spesialistoppfølgingen av voksne med PKU vært sentralisert til 
Rikshospitalet-Radiumhospitalet HF. Blodprøver til studien vil i samarbeid med overlege dr.med. 
Per Mathisen ved Medisinsk poliklinikk på Rikshospitalet inngå i denne spesialistoppfølgingen. 
Deltakere med samtykkekompetanse (mindre hjerneskade) vil bli innkalt til poliklinikken. For 
deltakere med alvorlig utviklingshemning, har vi imidlertid vurdert at reise til Rikshospitalet ikke er 
tilrådelig, og blodprøvene bes derfor tatt ved lokalsykehus eller hos fastlege. Regional komité for 
medisinsk forskningsetikk – Sør-Norge har tilrådd studien blant annet på denne bakgrunn.  
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For deltaker N.N., ønsker vi at blodprøvene tas ved lokalt sykehus eller hos fastlege.  
 
Rekvisisjon og prosedyre for prøvetaking, behandling av prøvene og analysering er vedlagt.  
 
• Studien omfatter også en kostregistrering som gjennomføres av ansatte i deltakers bolig.  
 
• I forbindelse med studien vil en fagperson og/eller pårørende bli intervjuet for å innhente 
informasjon relatert til PKU og behandlingen. Om mulig vil også deltakeren selv bli intervjuet.  
 
Utenom rutinemessige fenylalaninprøver, og en større blodprøve, vil studien ikke påvirke hverdagen 
til de dårligst fungerende i pasientgruppen.  
 
Blodprøvesvarene vil bli vurdert i forhold til kostregistreringen for hver enkelt deltaker, og 
tilbakemelding med eventuelle anbefalinger om endringer i medisinsk eller dietetisk oppfølging vil bli 
gitt fra overlege Per Mathisen og/eller Ingrid Wiig i samarbeid.  
 
Ansvarlig for gjennomføring  
Studien er vurdert og tilrådd av Regional komité for medisinsk forskningsetikk – Sør-Norge, og av 
personvernombudene ved Norsk samfunnsvitenskapelige datatjeneste og Rikshospitalet-
Radiumhospitalet HF. Blodprøvesvarene samles i en forskningsbiobank opprettet for denne studien.  
 
Samtidig vil den enkelte pasients blodprøvesvar inngå i den medisinske oppfølgingen og arkiveres i 
journal ved Rikshospitalet-Radiumhospitalet HF. Ansvarlig for studien og forskningsbiobanken er 
dr.med Bengt Frode Kase, avdelingsleder ved Senter for sjeldne diagnoser.  
 
Studien gjennomføres av mastergradsstudent Ingrid Wiig i samarbeid mellom Avdeling for 
ernæringsvitenskap ved Universitetet i Oslo og Senter for sjeldne diagnoser ved Rikshospitalet-
Radiumhospitalet HF. 
 
 
 
Vennlig hilsen 
 
 
 
Bengt Frode Kase   Per Mathisen   Ingrid Wiig 
Avd.leder, dr.med.   Overlege, dr.med.  Student, klinisk ernæringsfysiolog
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Appendix 12 
 Veiledning for blodprøvetaking i forbindelse med 
”Studie om diettbehandling hos voksne med sen behandlingsstart for PKU” 
 
Prøvene tas i samarbeid med overlege Per Mathisen ved Medisinsk poliklinikk på 
Rikshospitalet og inngår i den polikliniske oppfølgingen for voksne med PKU. Se vedlagte 
informasjonsskiv til deltakers fastlege. 
 
Rekvisisjoner er vedlagt og ferdig utfylt, bortsett fra pasientens navn.  
Blodprøvene bes tatt ved lokalt sykehus eller laboratorium som kan behandle prøvene i 
henhold til veiledningen nedenfor.  
Alle blodprøvene sendes og analyseres ved Rikshospitalet.  
(Hct og Hb kan analyseres lokalt siden de må analyseres inne 24 timer, ved lokal analyse er 
det viktig å føre opp svarene på rekvisisjonen for senere beregning av folat i erytrocytter). 
 
Svar går til dr. Mathisen, Medisinsk poliklinikk ved Rikshospitalet, og Ingrid Wiig, Senter for 
sjeldne diagnoser, Rikshospitalet. Hvis fastlegen ønsker kopi tilsendt direkte, må det skrives 
inn på skjemaet.  
 
Vi ønsker at blodprøvene tas fastende. Dersom det er umulig, ber vi om at det har gått minst 
4 timer siden siste måltid.  
 
Aminosyrer: 
Heparinblod, 0,5 -1 ml prøvemateriale. Prøven sentrifugeres og avpipetteres innen 30
minutter. 
Må fryses umiddelbart og sendes på tørris til Rikshospitalet. 
 
Hct, Hb og folat i erytrocytter: 
EDTA-blod – Hct og Hb må analyseres innen 24 timer – rør til folat i erytrocytter må 
lysbeskyttes, pakkes inn i folie. 
Hvis Hct analyseres lokalt, skal svaret føres på rekvisisjonen til Rikshospitalet for 
beregning av folat i erytrocytter. 
 
Sink: 
 Serum – glass til spormetaller er nødvendig  
 
 
Serum brukes til alle analysene utenom aminosyrer og Hct, Hb og folat i erytrocytter. 
 
Dersom transporten til Rikshospitalet drøyer, og det lokale laboratoriet selv måler hb/hct, bør 
serum/plasma til alle de øvrige analysene fryses og sendes frosset på tørris.  
EDTA-blod til folsyre i erytrocytter kan også fryses og sendes frosset, 
Det eneste som ikke tåler frysing er glasset til Hb/Hct. 
 
 
Se også veiledning på laboratoriehåndboken fra Avdeling for medisinsk biokjemi på 
Rikshospitalet: http://avd.rikshospitalet.no/klkinfo/labboka/KLK_labbok.htm
 
  
 
Eventuelt kan Ingrid Wiig kontaktes på 23 07 53 48/23 07 53 40 eller på e-post 
ingrid.wiig@rikshospitalet.no  
 
 
Ingrid Wiig, mai 2006
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The following phenylalanine free protein substitute products were used in the 
study, producers are listed alphabetically: 
Prekulab Ltd, Korsør, Denmark:   Avonil and PreKUnil 
SHS International Ltd, Liverpool, UK:  Lophlex and XPMaxamum 
Vitaflo International Ltd, Liverpool, UK:  PKUexpress 
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